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Hypoxia represents an important element of the solid tumor microenvironment and contributes to 
tumorigenesis and resistance to chemo- and radiation therapy.  Hypoxia can modulate cell cycle 
progression although the mechanisms involved remain unclear.  The Cdc25A dual specificity 
phosphatase promotes cell cycle progression by dephosphorylating and activating cyclin-
dependent kinases.  Cdc25A is the master regulator of the cell cycle and its disruption induces 
cell cycle arrest in cancer cells.  The recent observation that under hypoxic conditions, levels of 
Cdc25A protein and mRNA are decreased led to the hypothesis that hypoxia-mediated reduction 
in Cdc25A may represent a novel mechanism in the hypoxic regulation of the cell cycle.  Given 
the prominent role of Cdc25A in regulating the cell cycle and the proposed changes in Cdc25A 
protein and mRNA under hypoxic conditions, it was hypothesized that Cdc25A plays an 
essential role in hypoxia-mediated cell cycle arrest in human tumor cells.  The specific aims were 
to: 1) examine the mechanism of Cdc25A downregulation in response to hypoxia, 2) determine 
the role HIF-1α in Cdc25A regulation and cell cycle arrest, and 3) determine if Cdc25A 
downregulation is required for hypoxia-induced cell cycle arrest.  
Under hypoxic conditions, Cdc25A protein levels were specifically and reversibly suppressed.   
  v 
It was found that Cdc25A mRNA levels are significantly decreased by a p21-dependent 
mechanism.  In addition, suppression of Cdc25A was independent of p53.  Loss of Cdc25A 
protein occurred in the absence of checkpoint activation.  Recent evidence has linked the 
microRNA miR-21 to Cdc25A and hypoxia.  It is shown here that miR-21 was required for 
Cdc25A mRNA suppression in hypoxic colon cancer cells and miR-21 levels were increased 
under hypoxic conditions.  The HIF-1α transcription factor was not required for suppression of 
Cdc25A but must be present for hypoxia-induced cell cycle arrest.  Under hypoxic conditions, 
cells undergo p21- and miR-21- S-phase cell cycle arrest.  
This study proposes a novel mechanism of transient regulation of Cdc25A via the p21- and miR-
21-dependent regulation of mRNA levels in hypoxic cells leading to cell cycle arrest.  This 
previously unknown mechanism may confer protection from hypoxic conditions, contributing to 
cell survival and the observed resistance to chemo- and radiation therapy. 
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1 INTRODUCTION 
 
1.1 GENERAL INTRODUCTION – CANCER AND CELL DIVISION 
 
In 2008, an estimated 1,400,000 new cases of cancer were diagnosed and 565,000 people 
were expected to die from cancer, equivalent to 1500 cancer-related deaths per day1.  
These staggering figures make cancer the second most common cause of death in the 
United States, responsible for 1 in 4 deaths.  Despite a drop in cancer related deaths since 
2005 (1), cancer is expected to surpass heart disease as the leading cause of death2 in the 
United States. The American Cancer Society has predicted that half of all men and one-
third of all women will develop cancer during their lifetime3. The National institutes of 
Health have estimated that the overall annual cost of cancer in the U.S. to be $219.2 
billion in addition to the loss of human life.  The need for new detection methods and 
improved therapies for the diagnosis and treatment of cancer is self-evident.  To achieve 
this, we need to gain a greater understanding of the pathophysiology of cancer. 
Cancer is, in fact, not a single disease but a multitude of diseases with diverse physical 
manifestations characterized by the uncontrolled proliferation of cells.  These cells have 
acquired the ability to proliferate in the absence of growth signals or in the presence 
????????????????????????????????????????????????????????
1 American Cancer Society: 2008 Facts and Figures (http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf)   
2 The Nation’s Investment in Cancer Research: An Annual Plan And Budget Proposal Fiscal Year 2010 (http://plan.cancer.gov/) 
3 American Cancer Society: 2008 Facts and Figures (http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf)   
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signals intended to suppress cellular growth.  This proliferative advantage is believed to 
arise from single or multiple mutations in the cells genomic DNA resulting from normal 
and abhorrent cellular processes and a variety of environmental factors.  For the past 
three decades, cancer research has focused almost entirely on the cell itself without 
considering its surroundings.  Recently, it has become clear that cancer development 
relies heavily on the tumor microenvironment.  The present study attempts to relate the 
role of hypoxia, a component of the tumor microenvironment, with the complex cellular 
framework controlling cellular proliferation via modulation of the cell cycle. 
 
 
1.2 THE MAMMALIAN CELL CYCLE 
 
The cell division cycle or cell cycle allows for the transfer of genetic information to 
progenitor cells.  The successful transmission of an organisms’ genetic code is crucial for 
its survival.  The cell cycle is divided into two parts: firstly the replication of genetic 
material followed by segregation into two, identical daughter cells.  The mammalian cell 
cycle is divided into four distinct stages: G1, S, G2 and M phase.  During G1 the cell 
prepares itself for cell division, sensing extracellular signals prior to committing to cell 
division.  Cellular DNA is synthesized and the genome is replicated during S phase along 
with the cellular organelles and structures required for cell division.  In G2, the cell 
confirms that its DNA has been successfully replicated without errors and prepares for 
cell division.  During M phase, the cell segregates the duplicated DNA copies and 
organelles before physically splitting into two identical daughter cells, which share the 
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same genetic lineage as the parent cell.  The progression of a cell through the phases of 
the cell cycle towards cell division is stringently regulated to ensure successful cell 
division. 
 
 
1.3 CELL CYCLE REGULATION BY CYCLIN-DEPENDENT KINASES 
 
Transition from one phase of the cell cycle to the next is tightly controlled by a series of 
checkpoints capable of sensing defects in DNA synthesis and chromosome segregation.  
The principal catalysts driving progression through these checkpoints and subsequently 
through the cell cycle are the cyclin dependent kinases (Cdk).  Precise and timely 
regulation of Cdks is critical to ensure error-free cell division.  Cell cycle checkpoints act 
to specifically modulate the activity of the Cdks thus ensuring progression of the cell 
cycle and integration of intracellular and extracellular signals and ensure the seamless 
coordination of cell cycle processes in the event of environmental change or mechanical 
failure (2). The Cdks are a group of serine/threonine kinases that form active 
heterodimeric complexes following binding to cyclins.  Once activated, these Cdks 
phosphorylate cell cycle phase-specific proteins that promote cell cycle progression.  Cdk 
activity requires binding of regulatory subunits known as cyclins.  Cyclins are 
synthesized and destroyed in a specific circadian rhythm during the cell cycle thus 
controlling the timing of cell cycle progression.  Although human cells contain multiple 
loci encoding Cdks and cyclins (3) only a limited number of Cdk-cyclin complexes are 
truly required for cell cycle progression. 
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Specific Cdk-cyclin complexes are responsible for the different cell cycle transitions 
(Figure 1). During G1, mitogenic stimulation stimulates the expression of the D-type 
cyclins (D1, D2, and D3) that preferentially bind and activate Cdk4 and Cdk6 (4).  
Activation of these Cdk-cyclin complexes leads to the partial inactivation of the 
retinoblastoma proteins Rb, Rbl1 and Rbl2, allowing for the expression of cyclins E1 and 
E2 that bind to, and activate Cdk2 (5).  This complex has been shown experimentally to 
be essential for the progression from G1 to S phase (6).  Once DNA replication nears 
completion, Cdk2 is activated once more but this time by cyclin A2 allowing the cell to 
progress from S-phase into the G2 phase.  Activation of Cdk1 by the A-type cyclins is 
thought to facilitate entry into mitosis but it is the association of Cdk1 with the B-type 
cyclins that actually drives the cell through mitosis (3).  Cdk1 is the only Cdk required 
for cell cycle progression (7) with all others playing a redundant or overlapping role in 
the control of the cell cycle. 
Cdk regulation is mediated by phosphorylation and protein-protein interactions leading to 
both activation and inactivation.  The regulation of Cdk activity is initially mediated via 
the interaction with activating cyclins or Cdk Inhibitors (CdkI).  Inhibition of Cdks or 
Cdk-cyclin complexes by CdkIs can result in sequestration of Cdks from cyclins or 
suppression of activity respectively.  CdkIs can be divided into two classes based on their 
structural homology and Cdk targets.  The first class, the INK4 family, includes the 
inhibitors p15, p16, p18 and p19 and specifically inhibits Cdk4 and Cdk6 (8). The second 
class, the Cip/Kip family, is compromised of p21Cip1, p27kip1 and p57Kip2 and its members 
target the Cdk-cyclin-D, -E and -A complexes.  
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For the Cdks to become active they must first be paired with their cognate cyclins and 
CdkIs must be removed by sequestration or by proteasomal degradation (8).    For proper 
catalytic activity, Cdks must be phosphorylated on a threonine residue located in the T-
loop of the kinase (Thr161 on Cdk1 and Thr160 on Cdk2) by the Cdk activating complex 
(CAK; Cdk7-cyclin H), a serine/threonine kinase also involved in transcription and DNA 
repair (9).  This results in the partial activation of the Cdk and is followed by the addition 
of two inhibitory phosphorylations on Thr14 and Tyr15 of the Human Cdk1 by the Wee1 
and Myt1 kinases respectively (10-13).  Complete catalytic activation of the Cdk-cyclin 
complex is achieved by dephosphorylation of Thr14 and Tyr15 by the Cdc25 dual 
specificity phosphatases (Figure 2). 
 
 
1.3.1 THE CDC25 FAMILY OF DUAL-SPECIFICITY PHOSPHATASES 
 
The Cdc25 dual specificity phosphatase was first discovered in the fission yeast 
Saccharomyces pombe as the 25th gene discovered to regulate the cell division cycle (14).  
It was discovered that upon mutation of the Cdc25+ gene, yeast cells grew overly large 
and failed to undergo mitosis (14).  Conversely, introduction of extra copies of the 
Cdc25
+ gene resulted in smaller than usual cells that underwent premature mitosis (15-
17).  Evidence for Cdc25 being a phosphatase emerged from several studies examining 
the Wee+ phenotype in which yeast cells undergo premature mitosis before reaching 
normal size. When both Wee and Cdc25A were mutated, yeast cells regained a normal 
mitotic phenotype providing evidence that Wee and Cdc25 might have the opposite effect 
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and antagonize each other physiologically (14).  Arguably the most important evidence 
that Cdc25 was a phosphatase, however, came from studies of p34
Cdc2 
showing that 
dephosphorylation of p34
Cdc2-Tyr15 
was required for mitotic initiation (18).  Furthermore, 
the levels of Cdc25 were found to peak during mitosis, consistent with a role in mitotic 
induction (19).  This evidence was strengthened by the discovery that the Cdc25 genes 
from Homo sapiens, Drosophila, and Xenopus each encoded a protein with phosphatase 
activity against p34cdc2 (20-23).   The discovery that Cdc25 and its role in the eukaryotic 
cell cycle are highly conserved across species propelled the Cdc25 dual specificity 
phosphatases into the spotlight as regulators of the cell cycle. 
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Figure 1:?Cdks as drivers of the mammalian cell cycle.    
The mammalian cell cycle is composed of four stages: G1, S, G2 and M phase. The cell cycle is initiated by 
mitogenic stimulation leading to increased expression of cyclin D. Cyclins form complexes with Cdks 
driving progression through the phases of the cell cycle.  Activation of Rb by cyclin D/Cdk4 during the G1 
phase prepares the cell for DNA replication during S phase. 
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1.3.2 THE HUMAN CDC25 PHOSPHATASES 
 
Since the identification of Cdc25 as a phosphatase in humans, three isoforms of the 
Cdc25 have been identified:  Cdc25A, Cdc25B and Cdc25C (24, 25).  The Cdc25C 
isoform was discovered first using a degenerate oligonucleotide PCR approach based on 
the Drosophila Cdc25 and was found to share about 37% sequence homology with the 
fission yeast Cdc25+ mitotic inducer (24).  The isoforms Cdc25A and Cdc25B were 
identified by the same methodology in a different study (25).  The three human isoforms 
were found to restore initiation of mitosis in temperature sensitive cdc25+ mutants and 
were thus considered as human Cdc25s based on their homology and function (24).   
The human Cdc25 isoforms are encoded by distinct genes, each located on different 
chromosomes:  Cdc25A on 3p21, Cdc25B on 20p13 and Cdc25C on 5q31 (26-28).  In 
addition several mRNA splice variants have been discovered for each isoform (2 for 
Cdc25A; 3 for Cdc25B; 5 for Cdc25C) (29, 30) but the determinants and expression 
patterns of the splice variants’ protein products remain unknown.  It also remains unclear 
why humans and mammals have evolved three isoforms but adds a layer of complexity to 
the function of the Cdc25 family in humans. 
As mentioned above, there is some sequence homology between the human Cdc25 
isoforms and the Cdc25 sequence in fission yeast. This homology is limited to the C-
terminus of the protein.  Because of this, the human Cdc25 isoforms are divided into two 
primary structural domains: the N-terminal, with no sequence homology, and the C-
terminal, housing the catalytic domain (Figure 3).  The conserved amino acid sequences 
LIGD mark the boundary between the amino and carboxy domains of the phosphatases. 
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Figure 2:?Multistep activation of Cdk/cyclin complexes by the Cdc25 phosphatases. 
Myt1 and Wee1 kinases phosphorylate cyclins on T14 and Y15 rendering them inactive.  CAK provides an 
activating phosphorylation on T161.  Cdc25 phosphatases activate cyclins by dephosphorylating T14 and 
Y15 rendering the cyclin/Cdk complex active and allowing for cell cycle progression. 
 
The N-terminus region of the human Cdc25 isoforms is not necessary for catalytic 
activity.  Deletion experiments have shown that Cdc25s retain their catalytic activity in 
the absence of the N-terminus domain against small molecule substrate O-
methylfluorescein in in-vitro experiments (31).  As shown in Figure 3, the N-terminus 
region contains a nuclear localization sequence (NLS) as well as a nuclear export 
sequence (NES) that have been shown to play a role in the cellular localization the 
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protein in addition to multiple phosphorylation sites (32-35).  These phosphorylation sites 
are believed to play a role in the determination on localization, stability and catalytic 
activity of the protein.   
Despite the lack of homology in the N-terminus, all the human Cdc25s contain a 
consensus sequence that allows for interaction with the 14-3-3 family of proteins (36-38).  
These phosphothreonine and phosphoserine binding proteins regulate the intracellular 
localization of signaling proteins (39). In the case of the Cdc25s interactions with 14-3-3 
occur primarily in response cellular stresses and upon induction of DNA damage (36, 
37). 
The C-terminus catalytic domain of the human Cdc25s has been extensively 
characterized (Figure 3).  Crystal structures with better than 2.5 Å resolution have been 
determined for Cdc25A and Cdc25B (40, 41).  These two structures have been found to 
have significant homology in the folding patterns within the conserved regions but with 
some variation in the extremity of the C-terminus (41).  The structure of the catalytic 
domain varies from previously described phosphatases, including dual specificity 
phosphatases but resembles rhodanese, a sulfur-transfer protein (40).  The active site of 
Cdc25 also differs from traditional phosphatase structures in the active site of the enzyme 
is extremely shallow and there are no auxiliary loops extending over the active site (40, 
41).  Despite differences in the active sites, the Cdc25s contain the signature motif found 
in protein tyrosine phosphatases and dual specificity phosphatases (HCxxxxxR) (41). 
The catalytic mechanism of the Cdc25 phosphatases is similar to that of the dual 
specificity tyrosine phosphatases, however the Cdc25s preferentially dephosphorylate a 
monoprotonated phosphate in contrast to the more typical bisanionic phosphate substrate 
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(42).  The reaction catalyzed by Cdc25 involves the transfer of a phosphate from the 
phosphoamino acid to water.  The bisanionic phosphate is thought to bind in the loop of 
amide backbones and the positively charged arginine created by the HCxxxxxR motif 
(42).  As with other protein tyrosine phosphatases, the dephosphorylation of the substrate 
occurs by a two-step mechanism involving the formation of a phosphocysteine 
intermediate by attack of the catalytic thiolate on the phosphate moiety and expulsion of 
the leaving group (42, 43).  A catalytic acid is required to protonate the tyrosyl, threonyl 
or seryl oxygen’s in order to produce a good leaving group.  
 
1.3.3 CELL CYCLE CONTROL BY CDC25 PHOSPHATASES 
 
The mammalian cell cycle is regulated by the coordinated activity of all three Cdc25 
isoforms, their activity and expression levels being cell cycle-phase dependent (Figure 4).  
Initiation of the mammalian cell cycle occurs during G1 in response to mitogenic 
stimulation resulting in increased expression of cyclin D and formation of Cdk4-cyclin D 
complexes (Figure 1). There is some evidence that Cdc25A may be involved in starting 
the cell cycle by dephosphorylating Cdk4Tyr17 (44). 
Cdc25A is the main regulator of the G1/S transition by dephosphorylating and activating 
Cdk2/CylinE complexes, the rate limiting step for entry into S-phase (45).  In vitro 
studies have shown that Cdc25A is able to increase Cdk4/6 kinase activity toward Rb 
(45) and microinjection of anti-Cdc25A antibodies has been shown to prevent the 
transition into S-phase (46) and mutation of Cdk4Tyr17 negates the requirement for 
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Cdc25A (44).  This evidence certainly points to a role for Cdc25A in activating Cdk4 and 
initiating the cell cycle. 
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Figure?3??Mammalian Cdc25 phosphatases. 
The mammalian Cdc25A, Cdc25B, and Cdc25C phosphatases are encoded by three distinct genes and have 
specific roles in cell cycle regulation.  They comprise an amino terminal domain (grey), which serves a 
regulatory role and is the site of multiple phosphorylations, and a carboxy terminal domain (black), marked 
by a conserved -L-I-G-D- motif.  The carboxy terminal domain contains the canonical PTPase active site 
motif -H-C-X5-R- (where X is any amino acid).  Single letter amino acid abbreviations are used. 
Demarcated sequences in Cdc25B and Cdc25C identify 14-3-3 binding sites (serine phosphorylation site 
underlined) that facilitate checkpoint mediated cytoplasmic sequestration by interfering with the proximal 
nuclear localization signal sequences (NLS sequences are indicated with asterisks).  Nuclear export signal 
sequences are indicated with diamonds and the catalytic cysteine is marked by larger font.  Adapted from 
(31). 
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Experimentally, ectopic expression of Cdc25A results in an acceleration of the G1/S 
transition and Cdc25A is able to activate Cdk/cyclin complexes that are functional during 
G1 in vitro (45, 47).  Cdc25A protein levels and activity (47) surge during G1 and remain 
elevated through S-phase and have even been postulated to increase as cells enter mitosis 
(47, 48).  The phosphatase activity of Cdc25A beyond the G1/S transition appears to be 
driven by a positive feedback loop where Cdk2/cyclin E phosphorylates Cdc25A (47) 
however the phosphorylation site(s) on Cdc25A involved in potentiating its activity 
remain to be identified.   
S-phase was initially thought to be regulated primarily by Cdc25A and Cdc25B activity 
has been shown to appear during late S-phase and peak during G2 phase (Figure 4).  
Interestingly, downregulation of Cdc25B using antisense oligonucleotides in HeLa cells 
has been shown to cause S-phase delay (49) suggesting a role for the phosphatase in S-
phase.  The converse is also true:  microinjection of antisense cdc25B oligonucleotides in 
Fs68 fibroblasts failed to abrogate S-phase (50).  A similar discord exists with Cdc25C, 
which has been proposed to be a regulator of DNA replication (51) whereas other studies 
have found that microinjection of anti-Cdc25C antibodies had no effect on S-phase 
progression (47).  These conflicting findings raise the question as to whether the observed 
roles of Cdc25B and Cdc25C are not in fact cell type specific and not bona fide 
regulatory mechanisms.  This notion is supported by the fact that Cdc25B and Cdc25C 
knock out mice have no detectable defects in S-phase (52, 53). 
Regulation of G2 appears to me principally regulated by Cdc25A and Cdc25B (Figure 4). 
Overexpression of either phosphatase during S-phase or G2 results in initiation of mitosis 
(54, 55) whereas decreased expression results in delayed G2/M progression (55). 
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Mitotic initiation requires activation of Cdk1/Cyclin B and is regulated by all three 
Cdc25 isoforms in a distinct spatial and temporal fashion (Figure 4).  Activation of 
Cdk1/Cyclin B complexes is believed to occur through a positive feedback loop and 
regulation of Cdk1/Cyclin B complexes at multiple levels ensures precise timing of the 
cells entry into mitosis.  Cdc25B activity peaks during the G2 phase (50) and performs the 
first wave of activation of Cdk1/Cyclin B complexes at the centrosome (55).  This 
activation triggers the autocatalytic feedback loop with phosphorylation of Cdc25A and 
Cdc25C by Cdk1/Cyclin B culminating in full activation (20, 22, 56-59).  This sequence 
of events is supported by studies showing that both Cdc25B and Cdc25C are shuttled 
from the cytoplasm, where they are sequestered during interphase, to the nucleus at the 
beginning of mitosis (33, 60).  Cdc25A protein levels are stabilized during mitosis in 
contrast to the normally very rapid turnover (61).  Functional studies have also 
demonstrated that all three phosphatases are employed during for mitosis.  siRNA-
mediated depletion of Cdc25A inhibits entry into mitosis (61) and depletion of Cdc25B 
by the same method results in delayed entry into mitosis (55).  Finally the use of 
dominant negative Cdc25C mutants inhibit entry into mitosis (62).  The phenotypes of 
the various Cdc25 knockouts are discussed in Chapter 1.4.5. 
The Cdc25s are also postulated to have roles in several critical processes during cell 
division in addition to regulating Cdk/cyclin complex activity.  Cdc25A may regulate 
chromatin condensation because siRNA depletion of the phosphatase extends the period 
between centrosome separation and DNA condensation (55).  Cdc25B has been shown to 
regulate centrosome replication as overexpression of Cdc25B results in overreplication of 
centrosomes.  Furthermore, studies have shown that Cdc25B accumulation in the 
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cytoplasm causes centrosomal microtubule nucleation (62) Whereas Cdc25B inhibition 
results in altered microtubule spindle assembly leading to centrosomal separation delay 
(55, 63, 64). 
The Cdc25 phosphatases participate in the complex regulation of the mammalian cell 
cycle.  Experimental studies have provided important information into the function of 
each isoform and the role that they play in cell cycle transitions.  The mechanism of 
regulation of the Cdc25 phosphatases themselves adds a further level of complexity to the 
process of cell cycle progression but allows cells to respond to cellular insults and the 
extracellular milieu. 
 
 
1.3.4 REGULATION OF CELL CYCLE CHECKPOINTS BY CDC25 
PHOSPHATASES 
 
The replication of a cells genome and its segregation into daughter cells is essential for 
the survival of an organism. One of the major obstacles in this process is the constant 
genomic insult:  it is now known that the primary structure of DNA can be altered 
extensively by reacting with molecules in the normal cellular environment.  For example, 
at 37°C, about 18,000 purine residues are lost (65), 100 to 500 cytosines are deaminated 
(66) and over 1200 methylation event occur (67) per cell, each day. 
In addition, oxygen-free radicals, frequent by-products of cellular metabolism, react 
readily with DNA altering its structure and subsequently its coding sequence (68).  There 
are also a vast array of natural and man-made agents and sources that can assault the   
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Figure 4: Cell cycle regulation by the human Cdc25 phosphatases. 
The Cdc25 phosphatases dephosphorylate and activate cyclin/Cdk complexes at distinct but overlapping 
times during the cell cycle.  There is speculation that Cdc25A is required for initial activation of 
Cdk4/Cyclin D and Cdk2/Cyclin E complexes.  Cdc25A is predominantly responsible for the G1/S 
transition though recent evidence suggests that Cdc25B and Cdc25C may also be involved in this 
transition.  Cdc25A and Cdc25B coordinate progression through G2.  All three phosphatases regulate the 
G2/M transition and entry into mitosis.  Question marks indicate activities that are supported by limited 
experimental evidence, and dotted arrows illustrate known positive feedback phosphorylations by 
Cdk/cyclin complexes. The T-bar from Cdk1/cyclin A to Cdc25B represents inhibitory phosphorylation 
that targets Cdc25B for ubiquitin-proteasomal degradation, thus limiting its activity.  
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structure of DNA such as ultraviolet (UV) radiation from the sun, radiation, chemicals 
and environmental insults such as cigarette smoke and automobile exhaust. If left 
undetected and unrepaired, the resulting mutations are passed down to the cells 
progenitors.  To avoid this, cells have developed mechanisms or checkpoints, that act to 
stop or slow the progression of the cell cycle of cells containing damaged DNA or when 
cells are under subject to physiological stresses such as nucleotide depletion, replication 
fork stalling, aberrant DNA structures or failure of the chromosomal kinetichores to 
attach to the mitotic spindle. By slowing or halting the cell cycle, cells have a finite 
period of time in which to repair or rectify damage and either resume cycling or undergo 
apoptosis. 
The cell cycle checkpoints are positioned at the transitions between each phase of the cell 
cycle and are generally designated as the G1, S-phase, G2/M and M-phase checkpoints 
(Figures 1 and 4).  These checkpoints have evolved complex surveillance systems 
detecting either specific DNA structures indicative of ongoing repair or replication, or the 
presence of protein complexes engaged in repair or replication (69). These checkpoints 
serve to link up the cellular mechanisms that detect and screen for anomalies in the cells 
DNA with the cell cycle drivers thus ensuring high-fidelity DNA replication and 
distribution (69).  Signal transduction pathways are then triggered that prevent cell cycle 
progression by maintaining Cdk phosphorylation. 
The Cdc25 phosphatases are at the center of the checkpoint mechanism.  Cell cycle 
checkpoints are triggered by the detection of aberrant DNA, which in turn leads to 
recruitment of mediator proteins and the activation of checkpoint (Chk) kinases.  The 
Cdks are the principal drivers of the cell cycle and they are in turn activated by 
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dephosphorylation of Thr14 and Tyr15 by Cdc25 (Figure 2).  Upon checkpoint activation 
the Chk kinases phosphorylate Cdc25, inactivating the phosphatase and ultimately 
resulting in hyperphosphorylation of Cdks and induction of cell cycle arrest (Figure 5). 
The checkpoint-mediated inactivation of Cdc25s appears to be biphasic with a rapid 
phase, initiated within an hour and a sustained phase taking several hours to initiate.  The 
initial rapid phase is mediated by phosphorylation.  There are a number of Chk kinases 
involved in the checkpoint response. They include Glycogen synthase kinase 3? (GSK3?) 
(70), the Chk1 and Chk2 kinases (71, 72), and p38MAPK/MK2 (73, 74).   
The mechanism of checkpoint-mediated inactivation of Cdc25 is isoform specific.  
Cdc25A is regulated at the level of protein stability and rapidly degraded upon 
checkpoint activation by a p53 independent mechanism (48, 70-72, 75-78) (Figure 5).  
Cdc25A levels are rapidly decreased by polyubiquitylation and proteasome-mediated 
degradation. Conversely, Cdc25B and Cdc25C are phosphorylated on serine residues and 
sequestered in the cytoplasm by 14-3-3.  More specifically, Cdc25B is phosphorylated on 
Ser309 (79) and Cdc25C on Ser216 (36).   
Changes in Cdc25 protein stability are the not the only mechanisms of regulation in 
mammalian cells.  Sustained suppression of the Cdc25 phosphatases is mediated at the 
level of gene transcription.  Several studies have shown that the Cdk inhibitor p21 binds 
the Cdc25A promoter following DNA damage (80, 81) and in response to hypoxia where 
p21 has been shown to displace c-Myc from the Cdc25A promoter (82).  p53 has also 
been shown to transcriptionally repress Cd25A by binding to its promoter in a p21-
independent fashion in response to DNA damage (83). Cdc25C is transcriptionally 
repressed by p53 following DNA damage by two distinct mechanisms: the first involving 
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direct binding of p53 to the Cdc25C promoter and secondly via binding to a CDE/CHR 
(84).  To date there is no evidence for the transcriptional regulation for Cdc25B but 
recently several studies have proposed mechanisms of post-translational regulation of 
Cdc25B in response to checkpoint activation (85, 86). 
 
 
1.4 CDC25A:  MASTER REGULATOR OF CELL CYCLE PROGRESSION 
 
Cell cycle regulation is a complex process and as described above requires the 
coordinated activities of all three Cdc25 isoforms.  To gain a better understanding of the 
roles of each phosphatase, knock out models have been developed.  However, attempts to 
generate a Cdc25A knock out mouse have been unsuccessful suggesting that Cdc25A is 
essential for cell cycle progression and cell division (87). Studies with Cdc25A+/- mice 
have revealed no appreciable developmental defects and Cdc25A+/- mouse embryonic 
fibroblasts (MEF) exhibit normal cell cycle kinetics but have a shortened proliferative 
lifespan and prolonged G2/M arrest indicative of a possible role for Cdc25A in cell cycle 
resumption (87). With the development of inducible knock out systems, mice have been 
generated where Cdc25A is knocked in adulthood thus overcoming the embryonic 
lethality of traditional Cdc25A knock out attempts. Cdc25A -/- adult mice survived for 
approximately 1 week before dying from weight loss as a result dramatically decreased 
absorption in the small intestine (88).  The same study also established that Cdc25A is 
required in early stages of post implantation. 
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Cdc25B and Cdc25C have been successfully knocked out with no apparent defects 
suggesting that their roles in the cell cycle regulation are nonessential to ensure cell cycle 
progression and normal cell division. Cdc25B null mice develop normally and have no 
detectable phenotypes with the exception of sterility in females due to the absence of 
Cdc25B-mediated activation of the maturation-promoting factor (MPF) resulting in 
meiotic arrest (89).   Cdc25C null mice undergo normal cell cycle progression and cell 
division (52). Furthermore, Cdc25B/Cdc25C null mice (53) have been found to exhibit 
normal cell cycle progression and checkpoint responses. These findings provide strong 
evidence that Cdc25A is the only essential Cdc25 phosphatase and that is able to 
compensate functionally for the loss of Cdc25B and Cdc25C.  The precise regulation of 
Cdc25A levels and phosphatase activity is paramount for progression through the cell 
cycle as well as for modulation of the cell cycle under cellular stress. 
 
 
1.4.1 REGULATION OF CDC25A ACTIVITY 
 
As the master regulator of the cell cycle, Cdc25A activity must be stringently controlled. 
Aberrant Cdc25A activity suppresses apoptosis (90), promotes genomic instability (91), 
DNA damage (92) and tumorigenesis (61, 87).   
Cdc25A levels are regulated in response to intracellular and extracellular stimuli.  
Transcription of CDC25A is controlled by several transcription factors that stimulate 
transcription (c-Myc, STAT3 and E2F) and repress transcription (p53, p21, STAT3 and 
HIF-1?) by binding to the CDC25A promoter.  Expression of Cdc25A is cell cycle stage-
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specific. Cdc25A levels begin to increase during G1 and CDC25A transcription is 
mediated by E2F in response to mitogen stimulation (93). In the absence of mitogen 
stimulation, E2F is bound by members of the Rb family (p107 and p130) restricting its 
ability to induce transcription (94). c-Myc alone, (95) and in combination with STAT3 
also drives the transcription of CDC25A in response to growth factor stimulation (96). In 
combination with Rb, STAT3 results in the transcriptional repression of CDC25A (96).  
As mentioned earlier, p53 is also able to induce repression of CDC25A, albeit by a 
mechanism dependent on p53 binding but not to the promoter (83). Transcriptional 
repression of Cdc25A has also been described via the displacement of c-Myc from the 
CDC25A promoter by p21 in response to DNA damage and by HIF-1? (82, 97) under 
hypoxic conditions.  Expression patterns of Cdc25A fluctuate during the different phases 
of the cell cycle. It has been suggested that Cdc25A levels initially peak during the G1 
phase and then again during mitosis (46, 54).  
The regulation of Cdc25A half-life is an important mechanism in the regulation of the 
cell cycle by intracellular and extracellular signals and is modulated upon checkpoint 
activation during interphase.  Degradation of Cdc25A in response to checkpoint 
activation and in the G1, S and G2 phases of the cell cycle is mediated by Skp1-Cul1-
Fbox (SCF) ?-Transducin repeat containing protein (?-TrCP), a member of the SCF 
family of E3 ubiquitin ligases.  This process has been shown to be extremely rapid, in the 
order of minutes (98, 99). 
To be ubiquitinalated, Cdc25A must first be phosphorylated, but on different residues 
than those phosphorylated by Cdk/Cyclin complexes resulting in increased phosphatase 
activity.  The responsible kinases and the phosphorylated residues vary depending on the 
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phase of the cell cycle.  A number of residues have been identified within the N-terminus 
that must be phosphorylated in order for SCF?-TrCP to bind and ubiquitinate Cdc25A.  The 
process of phosphorylation is believed to occur in several stages: The first stage primes 
Cdc25A for degradation: Ser 76 is phosphorylated by GSK-3? (70) during G1 and by 
Chk1 during S and G2 phases (75). There is evidence that during S-phase, GSK-3 ? and 
Chk1 cooperate to regulate Cdc25A degradation in response to DNA damage (70) 
(Figure 5).  Mutagenesis studies have revealed that Ser 82 and Ser 88 must be 
phosphorylated in a second stage, in order for SCF?-TrCP to bind to Cdc25A during S-
phase in response to DNA damage. (76, 77). These serine residues form part of a 
conserved DSG motif (TDS82GFCLDS88PGPLD) that is recognized by SCF
?-TrCP (77). 
The kinases responsible for Cdc25A phosphorylation in response to DNA damage and 
environmental stress include Chk1, Chk2, GSK-3?, and p38 (100).  Each of these kinases 
has been shown to phosphorylate additional serine residues though the functions of these 
phosphorylations remain unclear. The kinase(s) responsible for cell cycle phase-
dependent regulation of Cdc25A have yet to be identified. Chk1 is thought to play a role 
in both the basal regulation and checkpoint-mediated regulation of Cdc25A (101, 102). It 
has also been suggested that Cdk2 may be the homeostatic regulator of Cdc25A based on 
its expression and activity profiles during the cell cycle (99). 
During mitosis, Cdc25A takes on a markedly stable form due to phosphorylation on 
Ser17 and Ser115 by Cdk1/Cyclin B, uncoupling Cdc25A from SCF?-TrCP-mediated 
ubiquitin-proteasome turnover (54).  Cdc25A in turn increases Cdk1/Cyclin B activity 
through a positive feedback loop, raising the activation threshold required for irreversible 
entry into mitosis. 
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At the end of mitosis Cdc25A levels decrease rapidly as a result of protein degradation by 
the ubiquitin-proteasome pathway.  This process is mediated by the anaphase-promoting 
complex/cyclosome (APC/CcdhI), a large multi-protein complex that functions as a 
ubiquitin ligase (103).  The CDHI portion of the complex recognizes a KEN box motif 
located on the N-terminus of the phosphatase (98).  The degradation of Cdc25A in the 
final stages of mitosis and the early stages of G1 is critical for attenuation of Cdk1 
activity helping the cell prepare for the next cell division cycle (100). 
 
 
1.4.2 CDC25A IN CANCER 
 
Malignancy is generally believed to arise either through the loss of tumor suppressor 
genes, the main function of which is to negatively regulate the cell cycle, or through the 
amplification of proto-oncogenes the main function of which is to promote and relay 
growth signals to the nucleus or a combination of both.  It is thought that most cancers 
develop as a result of the acquisition of a set of functional capabilities described by 
Hanahan and Weinberg:  the self sufficiency from growth signals; insensitivity to anti- 
growth signals; limitless replicative potential; evasion from apoptosis; sustained 
angiogenesis; and finally invasion and metastasis (104).  Deregulation of the cell cycle 
embodies several of these capabilities.  As a critical regulator of the cell cycle, Cdc25A 
has the potential to promote malignant transformation.  Indeed Cdc25A has been shown 
to have oncogenic properties, transforming normal MEFs with an oncogenic form of Ras 
or in an Rb-null background (61).   
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Figure 5: Checkpoint-mediated regulation of Cdc25A in response to genotoxic 
stress. 
DNA damage and genotoxic stresses result in activation of the Chk kinases, p38 and GSK3-?. Cdc25A is 
phosphorylated by these kinases, resulting in poly-ubiquitination by the SCF
?-TrCP
complex and proteasomal 
degradation. 
 
 
? 25 
Since Cdc25A overexpression was first described by Nagata (105), Cdc25A 
overexpression has been reported in numerous human cancers including colon (106), 
breast (107, 108), gastric (109), head and neck (110), lung cancers (111), esophageal 
carcinoma (112), non Hodgkin’s lymphoma (113) and neuroblastoma (114).  In addition 
to being overexpressed, Cdc25A levels in breast carcinomas are predictive of poor 
survival (107).   
As mentioned above, the proto-oncogenic properties of Cdc25A overexpression may lie 
in its ability to drive the cell cycle, promote cell division and drive malignancy.  This is 
compounded by the finding that Cdc25A may interact with the proto-oncogene Raf1 (61, 
115) as well as by regulation of the MAPK signaling cascade (116). Indeed, Raf1 and 
Cdc25A have been shown to co-localize within the cytoplasm and the former has been 
shown to be able to phosphorylate and activate Cdc25A (117).  Cdc25A has also been 
shown to dephosphorylate Raf1 following its activation by growth factor stimulation 
(115). These interactions may form a negative-feedback loop where the Ras-Raf-MAPK 
pathway promotes activation of Cdc25A which in turn negatively regulates Raf1, 
terminating MAPK activation and priming the cell for cell cycle progression (31). In cells 
transformed by Raf1, Cdc25A overexpression may play a role in decreasing the cytotoxic 
and cytostatic effects of aberrant MAPK activation while simultaneously promoting cell 
cycle progression (116, 118-120). 
From the perspective of the cell cycle, overexpression of Cdc25A may allow cells to 
bypass the growth-inhibitory signals transmitted by the Chk1 and Chk2 kinases in 
response to DNA damage, promoting genetic instability, and increasing the likelihood of 
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the cell acquiring genetic mutations leading to malignant transformation and acquiring 
growth advantage (71, 72). 
The spatial and temporal regulation of transitions between the different phases of the cell 
cycle must be strictly regulated in order to maintain genomic stability. It therefore places 
Cdc25A at critical position, where, in the event of a disruption of normal activity could 
result in a malignant phenotype of rapid proliferation and an insensitivity to cell cycle 
checkpoints (72).  Cdc25A provides a direct link not only between mitogenic signaling 
and the cell cycle but also the cellular microenvironment and is therefore ideally situated 
to facilitate cell transformation and malignant development. 
 
 
1.5 THE TUMOR MICROENVIRONMENT 
 
The tumor microenvironment is characterized by a poorly developed vasculature, leading 
to regions of hypoxia, decreased pH and inadequate nutrient levels as well as an 
accumulation of metabolic waste products (for example, carbonic and lactic acid 
produced during glycolysis) resulting in regions of acidosis in the tumor mass and 
surrounding areas.   
Tumor hypoxia constitutes a clinically relevant problem.  Direct evidence of a 
relationship between hypoxia and cancer was established by Vaupel and colleagues using 
oxygen electrodes (121, 122).  Low oxygen tension in tumors was associated with 
increased metastasis and poor survival in patients with solid tumors.  Resistance to 
chemo- and radiation therapy (123, 124) is also common feature of hypoxic tumors and 
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contributes to the difficulty in treating these tumors and decreased survival (125).  It is 
therefore highly pertinent to expand our understanding of the role of hypoxia in tumor 
development and resistance to treatment. 
Hypoxia is characterized by a reduction in the normal levels of tissue oxygen tension and 
occurs during acute and chronic vascular disease, pulmonary disease and cancer (125).  
Both chronic and acute hypoxia arises from an abnormal vasculature in tumors.  Chronic 
hypoxia arises due to the limited diffusion of oxygen from blood vessels into tissues 
whereas acute hypoxia arises from the dynamic nature of the aberrant tumor vasculature, 
such that vessels may become temporarily occluded down causing transient hypoxia in 
the surrounding tissue (126). 
 
 
1.5.1 TUMOR HYPOXIA 
 
Hypoxic regions are a common feature of solid tumors (127-129) and develop as a result 
of inefficient vascular development or an abnormal vascular architecture (126).  More 
specifically, the primary features of tumor physiology that lead to the development of 
hypoxia are limited arteriolar supply and arteriolar deoxygenation (130), relatively low 
vascular density and disorderly vascular architecture (131), oxygen consumption that is 
out of balance with oxygen supply (132) and an unstable blood supply (133).  Multiple 
studies have demonstrated that hypoxia is an independent adverse prognostic factor from 
tumor grade or treatment modality and positively correlates with tumor aggressiveness 
and poor disease survival (134-139).   
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Mammalian cells have evolved to utilize molecular oxygen for energy production.  Cells 
can respond to a variety of oxygen concentrations via alterations in both their metabolic 
states and growth rates.  Under hypoxic conditions, glucose is converted to lactate 
through the activity of glycolytic enzymes and lactate dehydrogenase A, a much less 
efficient means of generating ATP than via the complete oxidation of glucose by 
glycolytic enzymes, pyruvate dehydrogenase, the tricarboxylic acid cycle enzymes and 
the electron transport chain.  The switch from oxidative to glycolytic metabolism in 
hypoxic cells is mediated by HIF-1?, which will be discussed later in this section.  The 
absence of HIF-1? in hypoxic cells and blockade of the metabolic shift described above 
results in the toxic accumulation of reactive oxygen species and cell death (140). 
It has been proposed that hypoxia can alter cell proliferation in two ways: via apoptosis 
or through growth arrest (141).  In response to hypoxia, transformed cells undergo 
apoptosis via the p53 pathway (142) whereas non-transformed cells have been shown to 
undergo cell cycle arrest via the G1/S checkpoint without alterations in long-term 
viability (143).  During tumor growth, hypoxia can act as a selective pressure for the 
elimination of cells with wild-type p53 and the clonal expansion of cells with mutant or 
otherwise inactive p53 (144).  Cell cycle arrest under hypoxic conditions was originally 
attributed to the inhibition of nucleotide synthesis (145, 146).  However, it has since been 
found that inactivation of enzymes responsible for nucleotide synthesis occurs only under 
severe hypoxia (0.01% oxygen) or anoxia, but not under moderate hypoxia (0.1 to ? 1% 
oxygen) (143).  An increasing number of studies are shedding light on the molecular 
consequences of moderate hypoxia and have shown similarities with classic genotoxic 
stresses in terms of the cellular responses observed (141, 142, 147, 148).  Several of these 
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studies have described the induction of DNA stress checkpoints in response to hypoxia 
resulting in cell cycle arrest.  Studies have also shown that under moderate hypoxia, G1 
cell cycle arrest is induced via inhibition of Cdk/cyclin activity via an increase in CDKI 
such as p21 and p27 (143, 149) or through a reduction in critical cell cycle proteins such 
as Cyclin D, Cyclin E and Cdk4 (150).  
Another important element in the hypoxic response is the family of hypoxia-inducible 
factors (HIFs), major regulators of the cellular response to hypoxia.  HIF-1? is the most 
ubiquitously expressed of these transcription factors and acts as the master regulator of 
oxygen homeostasis in many cell types. HIF-1? is sensitive to decreased oxygen levels 
and is degraded rapidly by the ubiquitin proteasomal pathway under normoxic conditions.  
Hypoxia reduces the availability of HIF-1? to the Von Hippel-Lindau protein (pVHL), 
the recognition component of an E3 ubiquitin ligase complex, blocking HIF-1? 
degradation (151-153) and resulting in nuclear accumulation, and enhancement of 
transcriptional activity via binding to enhancer elements in target genes.  Under hypoxic 
conditions, oxygen-dependent prolyl hydroxylase domain proteins are inhibited, 
preventing the hydroxylation of prolines required for pVHL binding to HIF-1? (152).  
Once it stabilized under hypoxic conditions, HIF-1? forms a heterodimer with ARNT 
(aryl hydrocarbon receptor nuclear translocator) and with the cofactor p300 to regulate 
the transcription of a diverse group of hypoxia response element (HRE) -containing genes 
involved in pathways in systemic, local and intracellular oxygen homeostasis (154-156).     
Many of the genes regulated by HIF-1? allow a cell or tissue to adapt to the hypoxic 
conditions but also promote the survival of the tumorigenic phenotype found in cancer. 
Of the more than 60 targets of HIF-1?, many of these are involved in angiogenesis, 
? 30 
anaerobic glucose metabolism, metastasis, cell motility, iron metabolism, growth and 
survival, apoptosis, telomere maintenance and drug export mechanisms (157). 
Hypoxia induces the expression of various growth factors known to promote cell 
proliferation such as transforming growth factor ? (TGF-?) and platelet derived growth 
factor (158-160).  In addition HIF-1? itself is activated by the p42/p44 mitogen-activated 
protein kinases in response to extracellular growth factors leading to the transcriptional 
activation of HIF-1? target genes (161).  Hypoxia has been shown to increase the activity 
of several other mediators of cell proliferation including phosphatidylinositol 3-OH 
kinase (PI3K), and the oncogenic RAS pathway (162, 163).  HIF-1? involvement in the 
hypoxia-mediated effects of these growth factors has come primarily from HIF-1? null 
models, where the absence of HIF-1? negatively affects tumor growth.  Cells undergo a 
variety of biological response under hypoxic conditions including cell proliferation, 
angiogenesis, shifting from aerobic to anaerobic respiration, decreased apoptosis, 
migration and immortalization and cell cycle regulation (125, 155, 164).  Hypoxic 
regulation of the cell cycle will now be discussed in greater detail. 
 
 
1.5.2 HYPOXIC REGULATION OF THE CELL CYCLE 
 
The precise role of hypoxia and HIF-1? in cell cycle regulation under hypoxic conditions 
remains unclear.  It has been suggested that HIF-1? may be the primary determinant of 
cell cycle modulation under hypoxic conditions.  Cdk2 activity is completely inhibited in 
hypoxic cells (143, 165) and possibly mediated by a HIF-1?-dependent increase in p27 
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(141).  Elucidation of the role(s) of HIF-1? in the regulation of the cell cycle under 
hypoxic conditions has been complicated by a number of differing observations in both 
transformed and non-transformed cell lines.  It is not inconceivable that the role of HIF-
1? may differ in malignant cells compared with normal cells under hypoxic conditions.   
There is also evidence that hypoxia can regulate the cell cycle via activation of cell cycle 
checkpoints.  Severe hypoxia has been shown to induce ATR-dependent S-phase arrest in 
the absence of detectable DNA damage (or by a form of chromatin disruption not 
detectable by traditional comet assays) (166).  Although hypoxia does not appear to 
induce bone fide DNA damage, regions of single stranded DNA have been identified in 
hypoxic cells indicative of stalled replication forks (167). Hypoxia is frequently followed 
by periods of reoxygenation that elicit activation of an ATM and Chk2-dependent 
checkpoint response arresting cells at the G2/M checkpoint presumably due to 
reoxygenation-induced oxidative DNA damage (168).  In this study, the induction of cell 
cycle arrest also appears to be dependent on the presence of Cdc25C.   The activation of 
ATM and Chk2 has also been observed under hypoxic conditions in the absence of 
detectable DNA damage (169).   The activation of cell cycle checkpoints in cells under 
hypoxic conditions has also been linked to the activation of a number of DNA damage 
repair proteins including MLH1, NBS1 and BRCA1, indicative that hypoxia is causing 
alterations in DNA structure of not DNA damage itself (170, 171).  The Cdk inhibitors 
p21 and p27 have also been linked to the regulation of the cell cycle under hypoxic 
conditions.  Although neither is required for hypoxia-induced S-phase arrest, both p21 
and p27 appear to play a role in maintaining cell cycle arrest under hypoxic conditions 
(149).  Interestingly, it has been shown that p21 expression can be induced by HIF-1? by 
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a mechanism involving the displacement of c-Myc from the p21 promoter, presenting 
another level of regulation of genes lacking the canonical HRE and possibly regulation of 
the cell cycle by hypoxia (172).  A recent study has shown that Cdc25A mRNA levels are 
decreased under hypoxic conditions and that this decrease may occur through a similar 
mechanism of displacement of c-Myc from the Cdc25A promoter (82).    
The studies discussed above suggest that under hypoxic conditions, several regulatory 
pathways exist to drive tumorigenesis and control cell cycle progression in cancer cells.  
Recently, microRNAs (miRs) have been associated with tumor progression and several 
are upregulated under hypoxic conditions (173, 174).  In fact several of these miRs 
appear to be involved in the pathogenesis of cancer as well as being regulated by 
hypoxia. Of particular interest is miR-21, which is overexpressed in many cancers and 
increased by hypoxia (175).  This miR has recently been proposed as a putative regulator 
of Cdc25A (176, 177). 
 
 
1.6 GENE REGULATION BY MICRORNAS 
 
MiRs were originally discovered in Caenorhabditis elegans as essential regulators of 
larval development and have since been indentified in numerous organisms including 
vertebrates (178). To date, over 6000 miRs have been identified in humans (179) 
representing approximately 2% of human genes.  Based on in silico studies (180-182), it 
is estimated that up to 30% of human genes may be regulated by miRs, however, the role 
of miRs in the regulation of many of these genes remains to be validated.   
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miRs are a family of short (usually about 21-24 nucleotides) non-coding RNA molecules 
involved in the regulation of at least thirty percent of all translated genes (183, 184).  
These species act predominantly by blocking the translation of mRNA targets by a 
mechanism similar to that utilized by siRNA.  miRs are initially expressed as a primary 
transcript that is processed by the Drosha RNAase to generate a hairpin-RNA precursor 
(pre-miR).  Pre-miR precursors are then further processed by the RNAase III Dicer, 
resulting in the formation of mature duplexes (185). One of the mature strands becomes 
associated with the RNA-induced silencing complex (RISC), after which it is capable of 
interfering with gene expression at the transcriptional level (186).   
Much of the early work into the functions of miR was conducted in invertebrates where 
several miRs (Lin4 and Let7) were found to be important regulators of larval 
development in Caenorhabditis elegans.  When suppressed, these miRs promoted 
aberrant cell division without normal differentiation (187-189).  Studies in Drosophila 
melanogaster have identified miRs involved in tissue growth and suppression of 
apoptosis (190, 191).  Studies in mice and human cell lines have associated miRs with 
cellular differentiation and division functionally linking miR clusters to human cancers 
(192). 
 
 
1.6.1 MICRORNAS AND CANCER 
 
A number of miRs have been identified that can act as bona fide oncogenes (miR-17-92, 
miR-10b, miR-21) and tumor suppressors (miR-15-16 clusters).  miR-21 is upregulated 
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in a number of tumor types including breast, colon, lung, pancreas, stomach (174) as well 
as in a number cancer cell lines of various origins (174).  miR-21 levels have also been 
found to be high in a number of pathological conditions where aberrant cell growth and 
cellular stress are pathophysiological features such as  in cardiac hypertrophy (193, 194).  
A single gene located on chromosome 17q23.2, which overlaps with the protein-coding 
gene VMP-1, encodes the mature miR-21. The amplification of the 17q chromosomal 
region is associated with a number of cancers, however the genomic locus encoding miR-
21 is not amplified in most cancers including those expressing high levels of miR-21 
(176). This suggests that high levels of miR-21 is likely not due to gene amplification.  
Analysis of the consensus sequences within the miR-21 promoter region has identified 
several conserved enhancer elements, including binding sites for AP-1, C/EBP-?, nuclear 
factor-1, p53 and STAT3 (195).  Oncogenic transformation is frequently associated with 
the enhancement of endogenous AP-1 activity through various signal transduction 
pathways so it is possible that increased miR-21 levels may reflect increased AP-1 
activity in certain cancers.  Interestingly, miR-21 is consistently induced in response to 
hypoxia in breast and colon cancer cells (173) and both HIF-1? and AP-1 sites have been 
identified on the miR-21 promoter, and which are both upregulated by hypoxia.  This 
presents some clues as to the possible mechanism of hypoxia-dependent regulation of 
miR-21. 
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1.6.2 REGULATION OF CDC25A BY MICRORNAS 
 
Cell cycle regulation is tightly regulated by several mechanisms in response to mitogenic 
stimulation and extracellular conditions.  The regulation of Cdc25A by modulation of 
protein stability and gene expression has been discussed earlier.  Two recent studies have 
shown that Cdc25A may be a target for miR-21 (196). Cdc25A has been identified from f 
in silico approaches and validated in recent studies.  Cdc25A was found to be a target for 
miR-15a in human polycystic kidney and liver cells from humans and mice as a well as a 
number of other miRs (miR-34a, 103, 107, 195, 204, 326 and 331) (88). Another study 
has identified miR-21 as a regulator of Cdc25A in human colon cancer cell lines (Wang, 
P. unpublished).  Both miR-15a and miR-21 are known to be overexpressed in cancer and 
miR-21 ahs also been indentified as a hypoxia-responsive miR (HRM). 
 
 
1.6.3 MICRORNA REGULATION BY HYPOXIA 
?
As mentioned above, hypoxia is major feature of the tumor microenvironment and 
appears to play an important role in tumorigenesis through the regulation of a plethora of 
cellular functions.  To date, HIF-1? has been described as the key regulator of the cellular 
hypoxic response.  Recent studies have uncovered that in addition to the gene induction 
under hypoxic conditions, gene repression also appears to be playing a role in the 
hypoxic response (82, 197, 198).  The potential role of miRs in these repression events is 
? 36 
reinforced by the relative selectivity of repression, given that many genes continue to be 
expressed at normoxic levels under hypoxic conditions (199). 
Several studies have been performed to identify hypoxia-induced miRs providing a link 
between the control of gene expression and the response to hypoxia in cancer cells.  
These hypoxia-regulated miRs (HRMs) include miR-21, 23a, 23b, 24, 26a, s6b, 27a, 30b, 
93, 103, 106a, 107, 125b, 181a, 181b, 181c, 192, 195, 210 and 213 and have been found 
to be upregulated in breast and colon cancer cells in response to hypoxia (173, 199).  It 
must be noted that certain HRM appear to be cancer and cell type specific adding 
complexity to the role of these miRs in the hypoxic adaptation in cancer cells.   
The mechanism of miR regulation remains unclear although it has been suggested that 
miRs may be regulated by transcription factors. Indeed, c-Myc and the E2F transcription 
factor family have been found to regulate the expression of the miR-17-92 cluster (200, 
201).  Furthermore, identification of miR promoter regions is in its infancy with only a 
handful of studies being performed (202, 203).  An in silico study (173) has shown that in 
the predicted and known promoter regions of HRMs, the incidence of potential HIF-1 
binding sites was significantly higher than in those of miRs not regulated by hypoxia.  
miR-21 has been found to not only be upregulated in cancer but also in hypoxic cells 
(176, 177).  Given the potential role of miR-21 in regulating Cdc25A and the fact that it 
is upregulated by hypoxia, gaining a better understanding of the role of miR-21 in control 
of the cell cycle under hypoxic conditions is warranted. 
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1.7 STATEMENT OF THE PROBLEM AND HYPOTHESIS 
 
Hypoxia-mediated induction of cell cycle arrest is established but the mechanism of cell 
cycle arrest in tumor cells exposed to hypoxia remains unclear and a number of 
conflicting theories exist based on the heterogeneity of hypoxic conditions and cellular 
models used.   
Cdc25A is the master regulator of the cell cycle and its disruption has been shown to 
induce cell cycle arrest in cancer cells.  With the recent observation (82) that under 
hypoxic conditions, the levels of Cdc25A protein and mRNA are decreased has led to the 
hypothesis that hypoxia-mediated reduction in Cdc25A may represent a yet undescribed 
mechanism in the hypoxic regulation of the cell cycle.  It is possible that Cdc25A 
suppression may enable cancer cells to gain increased resistance against chemo- and 
radio- therapy, a phenomenon described in the treatment of numerous cancers (123, 124).  
Given the prominent role of Cdc25A in regulation of the cell cycle and the proposed 
changes in Cdc25A protein and mRNA under hypoxic conditions, I hypothesized that 
Cdc25A plays an essential role in the hypoxia-mediated cell cycle arrest in human 
tumor cells.  The specific aims of this dissertation were to 1) examine the mechanism of 
Cdc25A downregulation in response to hypoxia, 2) to determine the role HIF-1? in 
Cdc25A regulation and cell cycle arrest and 3) determine if downregulation of Cdc25A is 
required for the observed hypoxia-induced cell cycle arrest.  
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2 EXPERIMENTAL METHODS 
 
2.1 REAGENTS 
?
 Nocodazole, hydroxyurea, caffeine and doxycycline were purchased from Calbiochem.  
G418 and hygromycin B were obtained from Invitrogen.  Antibodies against Cdc25A, 
Cdc25C and Chk2 were obtained from Santa Cruz Biotechnology, Cdc25B and HIF-1? 
from BD Transduction Laboratories.  Antibodies against Chk1, phosphorylated Chk1 
(Ser345), and phosphorylated Chk2 (Thr68) were from Cell Signaling Technologies; the ?-
tubulin antibody was obtained from Cederlane Labs and anti-HA tag antibody from 
Covance.  Horseradish peroxidase-conjugated secondary antibodies were from Jackson 
ImmunoResearch. 
 
 
2.2 CELL CULTURE 
 
HCT116 human colon cancer cells were obtained from the American Type Culture 
Collection. The p53-/-, Chk2-/- and p21-/- HCT116 cells were a gift from Dr. Bert 
Vogelstein (Johns Hopkins University), and HIF-1? -/- HCT116 cells were a gift from 
Dr. Long Dang (University of Michigan). Cells were maintained in McCoy’s 5A medium 
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supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin/streptomycin, 
and 2 mmol/L L-glutamine in a humidified incubator at 37°C with 5% carbon dioxide. 
The DLD WT and DLD1 miR-21 KO cells, a gift from Dr. Zhenghe Wang (Case 
Western Reserve University), were also maintained in the above-mentioned conditions. 
HTA-21 cells, HeLa cells expressing HA-Cdc25A under a tetracycline repressor 
promoter were maintained in DMEM supplemented with FBS, 100 μg/mL G-418, 100 
μg/mL hygromycin B, and 100 ng/mL doxycycline in a humidified incubator at 37°C 
with 5% carbon dioxide.   
 
 
2.3 TRANSFECTION OF CELLS WITH PRE-MIR-21 
 
Pre-miR21 and pre-miR-224 complexes were obtained from Ambion.  Prior to 
transfection, 8x105 cells were plated on 6-well tissue culture dishes and allowed to adhere 
overnight.  Lipofectamine 2000 reagent (Invitrogen) was combined with Optimem 
medium (Gibco) and incubated at room temperature for 10 minutes.  Pre-miR complexes 
were added and the transfection mixture was allowed to incubate for 30 minutes at room 
temperature.  Cells were transfected with complexes for 6 hours in complete reduced-
serum media (1% FBS).  Following transfection, cells were incubated in complete media 
for 24 hours. 
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2.4 TREATMENTS AND INDUCTION OF HYPOXIA 
 
Cells exposed to hypoxia were incubated for the indicated periods of time in an InVivO2 
400 hypoxic workstation (Ruskinn Technology Ltd).  Cells were maintained under 1% 
oxygen and 5% carbon dioxide at 37°C in humidified conditions. Hypoxic conditions 
were confirmed using an iSTAT blood gas analyzer (Abbott).   For ultraviolet irradiation, 
cells were washed once with PBS before UV irradiation at 60 J/m2 using a UVC 
Crosslinker (Stratagene), followed by addition of fresh medium before incubation for 2 
hours and cell harvesting. 
 
 
2.5 WESTERN BLOTTING 
 
For Western blotting, cells were harvested by scraping into a modified RIPA buffer (50 
mM Tris pH 7.6, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 2 mM 
Na
3
VO
4
, 12 mM ?-glycerol phosphate, 10 mM NaF, 10 μg/mL aprotinin, 10 μg/mL 
leupeptin, 100 μg/mL 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, 10 
μg/mL soybean trypsin inhibitor, and 1 mM phenylmethylsulfonyl fluoride). Cells were 
lysed either by incubation on ice for 30 minutes with frequent vortexing or by sonication 
at 50% amplitude for 6 x 2 seconds on ice with a 2 second pause between pulses using a 
GEX-130 ultrasonic processor with a VC-50 2 mm microtip (Gene Q). Lysates were 
cleared by centrifugation at 13,000x g for 15 minutes, and protein content of the 
supernatant was determined by the method of Bradford. Total cell lysates (30 – 50 μg 
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protein) were resolved by SDS-PAGE and transferred to nitrocellulose membranes using 
an i-blot semi-dry transfer system (Invitrogen). The quality of transfer was confirmed by 
Ponceau staining of membranes followed by washing with ddH2O and TBS-T.  
Membranes were then blocked in 5% non-fat milk or 5% BSA as recommended by the 
primary antibody manufacturer, and incubated with primary antibodies overnight at 4°C. 
After washing 3 times for 5 minutes with 25 mL TBS-T, horseradish peroxidase-
conjugated secondary antibodies were added for one hour at room temperature before 3 
additional TBS-T washes and visualization with Pierce Enhanced Chemiluminescence 
Western Blotting Substrate (Pierce).  Chemiluminescence was detected using a LS3000 
luminescent image analyzer and analyzed using Multiguage software (Fujifilm).  
 
 
2.6 RNA ISOLATION AND QRT-PCR 
 
Total RNA was extracted with an RNeasy RNA isolation kit (Qiagen) and small RNA 
species for microRNA analysis were extracted using a mirVANA RNA isolation kit from 
Ambion. Isolated RNA was quantified using a SpectraMax M5 spectrophotometer 
(Molecular Devices).  
Quantitative PCR was performed using a one step protocol.  Briefly, total RNA was 
subjected to reverse transcription with iScript reverse transcriptase (BioRad) and 
amplification of cDNA with iTaq DNA polymerase with SYBR green (BioRad). All 
reactions were performed on an iQ5 Real-Time PCR Detection System (BioRad). The 
following primers  (IDT Technologies) were used:  Cdc25A forward 5’-
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CAAAATCCGTCTAGGAGCTGC-3’, reverse 5’-GTCTCTCCTTACCTGCCCAG-3’; 
CDC25B forward 5’-CACTCGGTCCCAGTTTTGTT-3’, reverse 
5’GTTTGGGTATGCAAGGCACT-3’; ?-actin forward 5’-
GTGTCACCAAAGCAAAGGCTTGGA-3’, reverse 5’-
ACAGGTTCTCTTCTGTGCTTGGGA-3’.  ? actin expression was used for 
normalization of each experiment.  Total RNA extracted using the mirVANA kit was 
subjected to reverse transcriptase PCR to generate cDNA with primers specific for miR-
21 and RNU-24 (Applied Biosystems).  PCR products were subsequently amplified from 
cDNA using a TaqMan Micro RNA assay (Applied Biosystems) according to the 
manufacturers protocol. The micro RNA RNU-24 was used as a control in these reactions 
and for normalization during data analysis.  The 2-??Ct method (31) of relative 
quantification was used to determine changes in mRNA and microRNA levels.  All 
experiments were conducted in triplicate and results presented as the mean ± SEM.   
 
 
2.7 FLOW CYTOMETRY 
 
Identification of mitotic cells was carried out by simultaneous staining of cells with 
propidium iodide (PI) (BD Pharmingen) and phospho-histone H3 using an anti-phospho-
histone H3 antibody (Upstate).  Cells were fixed overnight in 70% ethanol and 
permeabilized with 0.25% Triton X100 in PBS for 8 minutes on ice. After washing with 
1% bovine serum albumin (BSA) in PBS, cells were incubated with 1 μg anti-phospho-
histone H3 antibody for 2 hours.  Cells were subsequently washed with PBS containing 
? 43 
1% BSA before incubation with 1 μg anti-rabbit IgG Alexa 488 for 40 minutes in the 
dark. Finally cells were resuspended in 500 μl PI/RNAase staining buffer for 15 minutes.  
20,000 cells were analyzed by fluorescence activated cell sorting (FACS) using an 
EasyCyte Plus flow cytometer (Guava Technologies). ModFit LT cell-cycle analysis 
software (Verity Software House) was used to determine cell cycle phase distribution 
based on cellular DNA content. S-phase cells were identified using a BrdU flow kit (BD 
Pharmingen).  Briefly, staining with 10 μM bromodeoxyuridine (BrdU) was performed 
30 min prior to harvesting.  After harvesting, cells were permeabilized with the detergent 
saponin and fixed with 4% paraformaldehyde.  Cells were then treated with DNase to 
expose BrdU epitopes.  Immunofluorescence staining was achieved using a FITC-
conjugated anti-BrdU antibody followed by staining with 7-actinomycin-D for staining of 
total DNA content.  Cells were then resuspended in staining buffer and analyzed by 
FACS. WinMDI software (TSRI) was used for analysis and to determine both phospho-
histone positive cells and BrdU positive cells. 
 
 
2.8 STATISTICAL ANALYSIS 
 
Results are expressed as mean ± SEM of at least three independent experiments.  Anova 
and t tests were carried out using Graphpad Prism 5 (Graphpad Software). 
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3 REGULATION OF CDC25A PROTEIN LEVELS IN HUMAN TUMOR 
CELLS BY HYPOXIA 
 
3.1 INTRODUCTION 
 
Cdc25A plays a critical role in cell cycle regulation by acting as the link between 
intracellular and extracellular stimuli and the cell cycle.  Regulation of Cdc25A is 
mediated at the level of protein stability but also at the level of gene transcription.  In 
response to genotoxic stress such as DNA damage, ATM and ATR become active and 
phosphorylate the Chk kinases (Chk1 and Chk2), which in turn phosphorylate Cdc25A 
leading to its polyubiquitination and proteasomal degradation.  There is some evidence 
that this pathway is activated under hypoxic conditions and Cdc25A protein levels are 
suppressed in response to hypoxia.    Several studies have shown that hypoxia does not 
induce bone fide DNA damage but instead can induce replication fork stalling and 
replication stress, which is known to activate a checkpoint response.  The data presented 
below attempts to clarify the role of the Chk kinases in the regulation of Cdc25A under 
hypoxic conditions as well as the role of the CdkI p21, which is activated in response to 
replication stress. 
Whereas the mechanisms of regulation of Cdc25A protein stability have been extensively 
described, regulation of Cdc25A gene expression and transcription is poorly understood. 
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There is some evidence that Cdc25A gene expression is driven by c-Myc and that p21 
and HIF-1 can negatively regulate Cdc25A.  Recently Cdc25A was found to be a putative 
target for miR regulation by miR-21.   
The following study examines the regulation of Cdc25A by hypoxia.  I demonstrate that 
under hypoxic conditions, Cdc25A protein levels were depressed and that this was not 
due to activation of a checkpoint response. Cdc25A mRNA levels were also decreased in 
a p21-dependent fashion.  Examination of the role of miR-21 in this process revealed that 
miR regulation of Cdc25A mRNA levels represents a novel mechanism of regulation of 
Cdc25A in response to hypoxic stress. 
 
 
3.2 RESULTS 
 
3.2.1 CELL CULTURE MODEL OF HYPOXIA 
 
Tumor hypoxia was modeled by incubating immortalized cancer cells under reduced 
oxygen conditions.  There is a tremendous amount of heterogeneity in the simulation of 
hypoxia in cell culture models both from the perspective of the oxygen tension used and 
the types of cells studied. Experiments have been performed with oxygen concentrations 
ranging from 0.01 to 5% oxygen.  For this study, I chose to define hypoxia as 1% oxygen 
in a mixture of nitrogen and carbon dioxide because at extremely low oxygen conditions 
(< 0.01%) and anoxia (0%), the lack of molecular oxygen causes the shutdown of 
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nucleotide production and the cells hypoxic response is thought to be primarily mediated 
by the mitochondria resulting of this is rapid S-phase arrest and induction of cell death 
(204).  Moderate hypoxia allows for the study of hypoxic stress in the absence of 
mitochondrial sensing of hypoxia and ensures proper function of nucleotide synthesis 
pathways.   
The hypoxia-induced stabilization of HIF-1? was used a marker for a cellular response to 
hypoxic stress.  Figure 6 shows that within 1 hour of exposure to hypoxia (1% oxygen), 
HIF-1? protein levels were detectable and sustained for up to 24 hours of hypoxia.  As 
would be predicted, HCT116 cells under normoxic conditions did not have detectable 
levels of HIF-1? (Figure 6, 0 hours). 
 
 
?
 
Figure 6: Stabilization of HIF-1? protein with hypoxia. 
HCT116 cells were exposed to hypoxia (1% oxygen) for increasing time periods prior to cell lysis.  Whole-
cell lysates were resolved by SDS PAGE and HIF-1? levels were determined by Western blotting.  ?-
tubulin levels were used as a loading control.  The Western blot shown is representative of three 
independent experiments (N=3). 
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To maintain conditions as close to those found in a normoxic cell culture incubator, the 
InVivO2 400 chamber was maintained at 5% carbon dioxide 37°C, and humidified.  
Chamber oxygen levels were maintained at 1% oxygen but this did not provide any 
indication of the oxygen levels within the culture media of cells being exposed to hypoxia 
or maintained under normoxic conditions. To verify dissolved oxygen (pO2) levels in the 
culture medium, an iSTAT portable blood gas analyzer (Abbott) was used to measure 
pO2 levels.  Cells maintained at 1% oxygen were found to have significantly lower 
oxygen levels (?5%) compared with identical cells maintained under normoxic 
conditions (?20%) (Figure 7). 
 
 
?
 
Figure 7: pO2 levels are significantly decreased in cells exposed to hypoxia. 
HCT116 cells were maintained under hypoxic conditions for 24 hours or maintained under normoxic 
conditions for 24 hours.  Media samples were tested using an iSTAT portable gas analyzer and cG8+ 
cartridges.  Results shown represent the mean ± SEM of three independent experiments. 
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3.2.2 REDUCTION IN CDC25A PROTEIN LEVELS BY HYPOXIA 
 
Cdc25A protein levels were analyzed in HCT116 cells exposed to hypoxia for 0 to 24 
hours.  Cdc25A levels decreased with increasing duration of exposure to hypoxia and 
were undetectable after 24 hours by Western blot (Figure 8). 
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Figure 8: Cdc25A levels are decreased under hypoxic conditions. 
HCT116 cells were incubated under hypoxic conditions (1% O2) for 1-24 hr or maintained under normoxic 
conditions for 24 hours (0).  Cells were lysed and whole cell lysates were analyzed by Western blot for 
Cdc25A protein levels. The above western blot is representative of three independent experiments (N=3). 
Blots were probed for ?-tubulin as a loading control.  Cdc25A protein levels were quantified relative to ?-
tubulin by densitometry using Multiguage software and are indicated below the Western blot. 
 
3.2.3 LOSS OF CDC25A IS SPECIFIC UNDER HYPOXIC CONDITIONS 
?
The cellular response to hypoxia is aimed at the conservation of resources including 
amino acids required for protein translation.  With this in mind the levels of Cdc25B and 
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Cdc25C were analyzed in HCT116 cells exposed to hypoxia for 24 hours or maintained 
under normoxic conditions for 24 hours (Figure 9).  Whereas Cdc25A protein levels were 
decreased, Cdc25B and Cdc25C levels appear to be unaltered by a 24-hour exposure to 
hypoxia.  This finding indicates that the loss of hypoxia observed in not due to a non-
specific reduction in protein translation, which would result in global decrease in protein 
expression levels. 
 
 
?
 
Figure 9: Hypoxia does not affect Cdc25B and Cdc25C phosphatase levels. 
HCT116 Whole cell lysates were analyzed by Western blotting for Cdc25A, Cdc25B and Cdc25C levels 
following a 24-hour exposure to hypoxia or following 24 hours under normoxic conditions. The above 
Western blot is representative of three independent experiments (N=3).  
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3.2.4 LOSS OF CDC25A PROTEIN UNDER HYPOXIC CONDITIONS IS 
REVERSIBLE 
?
The hypoxia-mediated decrease in Cdc25A protein appears to be specific and similar 
decreases were not observed in the other Cdc25 phosphatase isoforms Cdc25B and 
Cdc25C.  Cdc25A levels were analyzed in cells that were initially exposed to hypoxia for 
24 hours and then returned to normoxic conditions for 0 to 24 hours to further understand 
the nature of the repression of Cdc25A under hypoxic conditions.  Cdc25A protein levels 
were detectable after 12 hours of reoxygenation suggesting that hypoxia-mediated loss of 
Cdc25A protein is reversible upon reoxygenation (Figure 10). 
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Figure 10: Hypoxia-mediated loss of Cdc25A is reversible upon reoxygenation. 
HCT116 cells were incubated under hypoxic conditions for 24 hours followed by increasing periods of 
reoxygenation (20% oxygen) before cells were lysed and analyzed by Western blotting for Cdc25A levels. 
(N=1). 
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3.2.5 P21 BUT NOT P53 IS REQUIRED FOR HYPOXIA-MEDIATED LOSS OF 
CDC25A 
?
p53 is known as the “guardian of the genome” and is stabilized following DNA damage 
and in response to cellular stress. As a major component of the tumor microenvironment, 
hypoxia represents a significant cellular stressor.  Exposure to cellular stresses and DNA 
damage results in an increase in p53 levels, which in turn drives the expression of p21 in 
these cells.  Both p53 and p21 have been demonstrated to suppress Cdc25A protein levels 
(80, 83) and p53 stabilization also activates Chk1 (205), known to be responsible for the 
phosphorylation-dependent degradation of Cdc25A.  The role of p53 in the modulation of 
the cell cycle by hypoxia and ultimately cell survival remains unclear as cellular stress is 
believed trigger a p53 response (205) but studies have shown that hypoxia-mediated 
modulation of the cell cycle does not require p53 (165).  An isogenic HCT116 cell line 
lacking p53 (p53 -/-) was subjected to 24 and 48 hours of hypoxia to establish whether 
p53 could be playing a role in the observed decrease in Cdc25A.  Analysis of Cdc25A 
protein levels by Western blotting revealed that in the absence of p53, cells retain the 
capability to down regulate Cdc25A in response to hypoxia (Figure 11).  These findings 
suggest that regulation of Cdc25A in response to hypoxia is independent of p53 and is in 
agreement with the work of others (148). 
The CdkI p21 is capable of transcriptionally repressing Cdc25A in response to DNA 
damage (80) and has been linked to the maintenance of hypoxia-induced cell cycle arrest 
and resumption (149).  Using an isogenic cell line that does not express p21 (HCT116 
p21 -/-), the role of the CdkI in the regulation of Cdc25A in hypoxic cells was examined.  
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As can be seen in Figures 12 and 21, the absence of p21 abrogated the loss of Cdc25A in 
hypoxic cells after 24 hours confirming that p21 played a role in this process. 
 
 
 
 
?
 
Figure 11: Hypoxia induced loss of Cdc25A occurs independently of p53. 
 p53-/- HCT116 cells were exposed to hypoxia (1% O2) for 24 hr or maintained under normoxic conditions.  
Whole cell lysates were analyzed for Cdc25A expression.  Relative expression of Cdc25A was quantified 
by densitometry as described above and normalized to ?-tubulin (N=3),* = p < 0.01.   
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3.2.6 LOSS OF CDC25A OCCURS IN THE ABSENCE OF CELL CYCLE 
CHECKPOINT ACTIVATION 
 
Regulation of Cdc25A following checkpoint activation has been extensively described.  
As shown in Figure 5, Cdc25A is phosphorylated and targeted for proteasomal 
degradation by a number of checkpoint kinases including Chk1 and Chk2 that have been 
shown by others to be involved in hypoxia-mediated cell cycle arrest (167, 169). I 
analyzed levels of Chk1 and Chk2 phosphorylation in cells exposed to hypoxia to 
determine if the observed loss of Cdc25A was due to checkpoint activation.  Hypoxia did 
not induce an increase in the phosphorylation of Chk1 or Chk2 at Ser345 and Thr68 
respectively or change overall kinase levels, compared with UV irradiation that increased 
both Chk1 and Chk2 phosphorylation levels (Figure 12).  UV irradiation is known to 
induce a checkpoint response and cause the degradation of Cdc25A (206) and was used 
as a positive control for DNA damage-induced checkpoint activation and loss of Cdc25A.  
As expected in response to UV irradiation, Chk1 and Chk2 phosphorylation levels were 
significantly increased, indicative of checkpoint activation, and Cdc25A levels were 
suppressed by 2 hours after treatment, consistent with increased degradation of the 
phosphatase (Figure 12).   
These findings indicate that 1) loss of Cdc25A under hypoxic conditions did not require 
Chk kinase activation and 2) that HCT116 cells were competent to activate the 
checkpoint response following induction of genotoxic stress and DNA damage by UV 
irradiation.  In the absence of a viable Chk1 null cell line, a pharmacological blockade of  
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Figure 12: Cdc25A downregulation by hypoxia does not require Chk1 or Chk2 
activation. 
Cell lysates from WT and p21-/- HCT116 cells exposed to hypoxia were analyzed for increases in Chk1 
and Chk2 phosphorylation.  WT HCT116 cells were treated with UV irradiation (60 J/m2) and then 
incubated for 2 hours prior to harvesting cells to confirm that HCT116 cells have a functional checkpoint 
response. The above Western blot is representative of three independent experiments (N=3).  
 
Chk1 was used to confirm that Chk1 was not required for the observed loss of Cdc25A 
under hypoxic conditions.  HCT116 cells were exposed to hypoxia in the presence of the 
ATM/ATR-Chk1 inhibitor caffeine (5 mM) (207) for the duration of the hypoxic 
exposure.  As can be seen in Figure 13, caffeine treatment did not prevent the loss of 
Cdc25A under hypoxic conditions indicative of Chk1 independence.  Interestingly, 
caffeine alone appeared to repress Cdc25A levels under both normoxic and hypoxic 
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conditions (lanes 2 and 4), which was not expected following treatment with an agent that 
prevents checkpoint kinase activation. Inhibition of ATM and ATR by caffeine would on 
the contrary be expected to have increased Cdc25A protein levels. 
 
 
?
 
Figure 13: Caffeine treatment does not block hypoxia-mediated Cdc25A loss. 
HCT116 cells were pretreated with 5 mM caffeine for 30 minutes to block ATM/ATR Chk1 basal activity 
and then exposed to hypoxia (24 hours) in the presence of caffeine at the same concentration. The above 
Western blot is representative of three independent experiments (N=3).  
 
The role of Chk2 in the hypoxia-induced loss of Cdc25A was determined thanks to the 
existence of the isogenic Chk2 -/- HCT116 cell line. Upon exposure to hypoxia, Chk2 -/- 
cells downregulated Cdc25A to the same extent as the WT cells albeit with much slower 
kinetics of downregulation as can be seen in Figure 14. 
Checkpoint activation in response to DNA damage or replication stress results in a 
dramatic decrease in Cdc25A protein levels via increased degradation (71).  I utilized a 
cell line capable of ectopically expressing HA-tagged Cdc25A to test whether hypoxia 
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increases Cdc25A protein degradation.  The HTA-21 cells are HeLa cells expressing HA-
Cdc25A under a tetracycline repressor promoter.  Upon removal of doxycycline, these 
cells readily overexpress HA-tagged Cdc25A under control of a constitutive promoter.  
These cells were exposed to hypoxia for 24 hours in the presence or absence of 
doxycycline.  As expected, the cells cultured without doxycycline had high levels of HA-
tagged Cdc25A that was degraded when these cells were exposed to UV irradiation (60 
J/m2) (Figure 14). However, when overexpressing cells were cultured under hypoxic 
conditions, levels of HA-tagged protein did not decrease.  This finding suggested the 
mechanism of hypoxia-induced suppression of Cdc25A did not involve increased 
Cdc25A protein degradation as would be expected with checkpoint activation or via a 
mechanism leading to the phosphorylation of Cdc25A and subsequent degradation. 
Taken together the finding that neither Chk1 nor Chk2 were required for hypoxia-
mediated loss of Cdc25A along with the absence of Chk1 or Chk2 activation or increased 
degradation of HA-Cdc25A in response to hypoxic stress suggested that this phenomenon 
might be occurring by a mechanism that did not require checkpoint activation and did not 
affect Cdc25A stability. 
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Figure 14: Chk2 is not required for hypoxia-mediated loss of Cdc25A. 
Lysates from WT and Chk2-/- HCT116 cells exposed to increasing time periods of hypoxia were analyzed 
by Western blot for Cdc25A protein levels. The above Western blot is representative of three independent 
experiments (N=3).  Cdc25A protein levels were quantified relative to ?-tubulin by densitometry using 
Multiguage software and are indicated above the Western blot. 
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Figure 15: Hypoxia does not increase protein degradation. 
HTA-21 cells containing a Tet-repressor expression system allowing for ectopic expression of Cdc25A in 
the absence of doxycycline.  Cells were exposed to hypoxia (24 hours) or maintained under normoxic 
conditions in the presence or absence of doxycycline followed by harvesting of whole cell lysates and 
analysis of Cdc25A protein levels by Western blot.  HIF-1? levels were analyzed to confirm induction of 
hypoxia.  Cells exposed to UV irradiation were treated with 60 J/m2 and incubated for 2 hours prior to 
harvesting of protein.  The above Western blot is representative of three independent experiments (N=3).  
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3.2.7 SUPRESSION OF CDC25A MRNA LEVELS BY HYPOXIA 
 
Regulation of Cdc25A under hypoxic conditions does not appear to be regulated by 
changes in protein stability mediated as a result of cell cycle checkpoint activation.  
There are reports that Cdc25A expression can be controlled by several mediators 
including c-Myc, which has been described to drive Cdc25A expression and p21, which  
has been shown to repress Cdc25A expression by displacing c-Myc (80, 81) and is 
essential for observed hypoxia-mediated loss of Cdc25A.   
Cdc25A mRNA levels were analyzed by real time quantitative PCR and expression was 
normalized to ?-actin.  Analysis of mRNA levels was done using the comparative CT 
method (208) and relative reaction amplification efficiencies were calculated to validate 
the analysis and reliability of the data. 
Cdc25A mRNA levels were examined in WT and p21 -/- HCT116 cells after a 24 hour 
exposure to hypoxia and compared with mRNA levels in the same cells under normoxic 
conditions.  Cdc25A mRNA levels were significantly reduced after 24 hours of hypoxia 
compared with normoxic WT cells (Figure 16A).  However, in the p21 -/- HCT116 cells, 
no statistically significant change in Cdc25A mRNA levels was observed (Figure 16A).  
This finding was consistent with the requirement of p21 for loss of Cdc25A under 
hypoxic conditions.  Cdc25B mRNA levels were analyzed in WT HCT116 to determine 
the specificity of the observed repression of Cdc25A mRNA and as expected there was 
no change in Cdc25B mRNA levels with hypoxic exposure compared with normoxic 
cells (Figure 16B).   
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Figure 16: Hypoxia-mediated decrease in Cdc25A mRNA levels. 
Total RNA was isolated from cells exposed to hypoxia  (1% O2) or maintained under normoxic (20% O2) 
conditions. (A) Cdc25A and (B) Cdc25B expression levels were analyzed by quantitative real-time PCR. 
Expression was normalized to ?-actin and relative expression determined by the Livak method. * = P<0.05; 
N=3.  
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3.2.8 MIR-21 AS A REGULATOR OF CDC25A IN CANCER CELLS UNDER 
HYPOXIC CONDITIONS 
 
Cdc25A has been proposed as a target for miR-21.  miR-21 has recently been shown to 
be upregulated in hypoxic cells although the consequences of elevated mir-21 are not 
established (173).  To test the hypothesis that miR-21 may represent a novel regulator of 
Cdc25A under hypoxic conditions I examined the effect of hypoxia on Cdc25A protein 
levels in WT and miR-21 knock out (KO) cells.  As can be seen in Figure 17, WT DLD1 
cells have decreased Cdc25A protein levels after 24 hours of hypoxia whereas the DLD 
mir-21 KO cells did not exhibit a decrease in Cdc25A protein levels.  This finding 
suggested that miR-21 was indeed a regulator of Cdc25A and was required for the 
suppression of Cdc25A by hypoxia. 
?
 
Figure 17: Hypoxia-mediated loss of Cdc25A in DLD1 cells requires miR-21. 
WT and miR-21 KO cells were exposed to hypoxia (1% O2) for 24 hours. Cells were lysed and whole-cell 
lysates were examined by Western blot for Cdc25A protein expression. Cdc25A protein levels in WT and 
miR-21 KO DLD1 cells under normoxic were used as control.  The above Western blot is representative of 
three independent experiments (N=3).  
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miRs regulate their targets by degrading mRNAs.   I analyzed Cdc25A mRNA levels to 
further explore the role of miR-21 as a regulator of Cdc25A under hypoxic conditions in 
WT and miR-21 KO DLD1 cells following exposure to hypoxia.  WT cells were found to 
have significantly reduced Cdc25A mRNA levels compared to normoxic cells whereas 
the miR-21 KO cells had no detectable decrease in Cdc25A mRNA levels (Figure 18). 
I performed real time quantitative PCR to ascertain if hypoxia was inducing an increase 
in miR-21 levels in HCT116 cells using primers specific for miR-21 and as a control the 
miR RNU-24.  It was found that with a 24 hour exposure to hypoxia, miR-21 levels were 
increased 3-fold in the WT HCT116 cells whereas levels of the control miR RNU-24  
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Figure 18: Decreased Cdc25A mRNA levels in WT but not miR-21 KO DLD1 cells. 
DLD1 WT and DLD1 miR-21 KO cells were incubated under hypoxic conditions for 24 hours and mRNA 
levels were determined by quantitative real-time PCR. Expression was normalized to ?-actin and relative 
expression determined by the Livak method. * = P<0.05; N=3.  
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remained unchanged by hypoxia (Figure 19).  This finding is in agreement with the work 
of others and establishes a possible role for miR-21 in the hypoxic regulation of Cdc25A 
in two independent colon cancer cell lines.   
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Figure 19: Increased levels of miR-21 in hypoxic HCT116 cells. 
miR-21 levels were determined using a TaqMan real-time PCR microRNA assay.  WT HCT116 cells were 
cultured under normoxic conditions or hypoxic conditions for 24 hours followed by harvesting of total 
RNA using the mirVANA RNA isolation assay. miR-21 (A) and RNU-24 (B) were analyzed using 
TaqMan probes by quantitative real-time PCR and relative expression was analyzed by the Livak method.  
* = p < 0.05. 
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To determine if restoration of miR-21 in miR-21 null could restore the phenotype of 
hypoxia-mediated Cdc25A loss, I transfected miR-21 KO DLD1 cells with a pre-miR-21 
complex or a pre-miR-224 complex as control and then exposed these cells to hypoxia. 
As can be seen in Figure 20, cells transfected with the control pre-miR-224 did not 
repress Cdc25A under hypoxic conditions but cells transfected with pre-miR-21 had 
decreased Cdc25A levels under both hypoxic and normoxic conditions.  These results 
indicate that reintroduction of miR-21 into cells restores the cells ability to repress 
Cdc25A under hypoxic conditions. 
 
 
?
 
Figure 20: Expression of miR-21 in mir-21 KO cells restores cdc25A-loss phenotype. 
DLD1 miR-21 KO cells were transfected with a pre-miR-21 complex followed by exposure to hypoxia for 
24 hours or maintained under normoxic conditions for 24 hours.  Control cells were transfected with pre-
miR-224 to control for non-specific effects of transfection.  Cdc25A levels were determined by Western 
blotting.  The above western blot is representative of three independent experiments (N=3).  
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3.3 DISCUSSION 
 
Numerous studies have described the modulation of the cell cycle in primary and 
immortalized cells exposed to hypoxia (141, 143, 148, 149, 155, 165-167, 169-171).  The 
majority of studies have focused on severe hypoxic conditions (<0.1% oxygen) and have 
proposed that modulation of the cell cycle under hypoxic conditions is mediated by 
checkpoint activation in response to DNA damage and aberrant structures located on 
DNA such as stalled replication forks.  Although activation of ATM, ATR and their 
downstream mediators has been described in response to hypoxia, the role of the Cdc25 
phosphatases has not been extensively studied. In the present study, Cdc25A but not 
Cdc25B or Cdc25C was repressed under hypoxic conditions. 
I developed a cell culture model of hypoxia in colon cancer cells to address the issue of 
hypoxia-mediated regulation of Cdc25A.  HCT116 cells exposed to 1% oxygen for up to 
48 hours resulted in a significant decrease in pO2 levels in the cell culture medium and 
HIF-1? levels increased within 1 hour of hypoxic exposure and remained elevated for 
over 24 hours.  Moderate hypoxia caused a reversible decrease in Cdc25A protein levels 
in the colon cancer cell lines HCT116 and DLD1.  The observed repression was specific 
to Cdc25A as the Cdc25B and Cdc25C phosphatase levels were not affected by hypoxia.  
This finding indicates that repression of Cdc25A in response to hypoxia is not the result 
of a global suppression in protein translation or gene expression that has been reported in 
cells exposed to cellular stresses including hypoxia (209). 
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This study has shed some light on the mechanism of regulation of Cdc25A under hypoxic 
conditions.  Previous studies have described the regulation of Cdc25A through activation 
of checkpoints resulting in the phosphorylation, polyubiquitination and degradation of the 
phosphatase.  This study demonstrates that colon cancer cells exposed to moderate 
hypoxia did not activate cell cycle checkpoints as indicated by the absence of Chk1 and 
Chk2 activation in addition to the fact that Cdc25A loss is not suppressed in Chk2 -/- 
cells or following pharmacological inhibition of the ATR-Chk1 pathway by caffeine.  
The absence of checkpoint activation was not entirely unexpected given that a number of 
studies have failed to show that hypoxia induces DNA damage but instead causes 
replication fork stalling (166-169). The cells used in this study were however, capable of 
inducing degradation of Cdc25A following induction of DNA damage with UV 
irradiation, indicative of responsive checkpoint pathways.  Others have shown that under 
the same conditions no significant DNA damage is detected until cells are returned to 
normoxic conditions upon which substantial induction of DNA damage is observed 
(148). Reoxygenation-induced DNA damage can be induced by reactive oxygen species, 
which are dramatically increased in reoxygenated cells. This phenomenon may also 
account for the delayed return of Cdc25A upon reoxygenation and slightly decreased 
levels at 24 hours post reoxygenation. 
p21 and p53 play an important role in the cellular response to genotoxic stress.  Their 
involvement in regulation of Cdc25A and the cell cycle remains to be fully characterized. 
Isogenic cell lines lacking p21 (p21 -/-) or p53 (p53 -/-) were cultured under hypoxic 
conditions to test the involvement of p21 and p53.  The absence of p53 did not affect the 
loss of Cdc25A but the absence of p21 abolished the hypoxia-mediated loss of Cdc25A.  
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p21 has been shown to repress Cdc25A gene expression by displacing c-Myc from the 
Cdc25A promoter (80, 81) in response to genotoxic stress and has been shown to be 
upregulated under hypoxic conditions (147). It is therefore possible that p21 may regulate 
the expression of Cdc25A under hypoxic conditions in addition to genotoxic stress. 
Given the absence of checkpoint activation after exposure to hypoxia and no detectable 
increase in Cdc25A protein degradation as determined by ectopic expression of HA-
Cdc25A, the regulation Cdc25A mRNA levels was examined.  WT HCT116 cells have 
significantly decreased Cdc25A mRNA levels after 24 hours of hypoxia whereas Cdc25B 
mRNA levels remained unchanged again demonstrating that the loss of Cdc25A is a 
specific process and not part of the global repression of protein translation and gene 
expression in response to environmental stress (210).  It is also interesting to note that 
despite the dependence on p21 for Cdc25A repression, p21 itself did not appear to be 
increased by hypoxia. In response to DNA damage by agents such as SN38 and 
doxorubicin, p21 protein levels are elevated and Cdc25A mRNA levels are decreased 
(80).  The findings in this study are in agreement with the findings of others that p21 
protein levels are not increased in response to hypoxia (149).  It remains to be determined 
if repression of Cdc25A by p21 requires and increase in the protein levels of the CdkI as 
well as how hypoxic exposure leads to the p21-dependent decrease in Cdc25A.  One 
potential explanation for a hypoxia-mediated change in p21 activity in the absence of 
detectable protein upregulation is that changes in the redox state of cells can result in 
changes in p21 activity.  Indeed, p21 has been shown to be S-nitrosylated by nitric oxide 
resulting in increased p21 activity and downstream signaling (211, 212). The redox-
mediated post transcriptional regulation of p21 levels has also been described (213). It is 
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therefore possible that under hypoxic conditions, which is paradoxically associated with 
elevated levels of reactive oxygen species and oxidative stress (214), p21 activity might 
be increased in the absence of increased p21 transcription. The involvement of p21 in the 
regulation of the cell cycle is discussed further in Chapter 5.  My study represents the 
first report of p21 and miR-21 acting to decrease Cdc25A mRNA levels under hypoxic 
conditions.  To date the regulation of Cdc25A in response to extracellular stimuli and 
potential genotoxic stress has focused primarily on increased protein degradation as a 
consequence of checkpoint activation.  The kinetics Cdc25A protein loss were consistent 
with suppression of mRNA levels, which would require substantially more time than the 
polyubiquitination and proteasomal degradation of Cdc25A in response to checkpoint 
activation given the need for upregulation and processing of miR-21 and a reduction in 
Cdc25A transcription by p21.  The regulation of Cdc25A by miR-21 represents a novel 
level of regulation in response to extracellular stimuli that may allow for cell cycle 
regulation. Although the existence of a relationship between p21 and miR-21 remains to 
be established, it is possible that these mediators of Cdc25A gene expression may 
function in concord to reduce levels of Cdc25A at the onset of hypoxia and subsequently 
maintain suppression of the phosphatase until normoxic conditions are restored.  Indeed, 
it has been proposed that whereas p21 is not required for the induction of cell cycle arrest 
in response to hypoxia, it may be responsible for the maintenance of cell cycle arrest and 
for preventing premature cell cycle resumption (149).  By reducing Cdc25A, hypoxic 
cells may be protected from the potential genetic instability that would arise if DNA 
replications were allowed to proceed under hypoxic conditions increasing the likelihood 
of replication fork stalling (215).   
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The adaptation of cells to changes in their surroundings is an important feature in the 
maintenance of genomic stability and ultimately survival of the organism.  But the 
regulation of Cdc25A by hypoxia represents a double-edged sword: the sustained 
repression of Cdc25A under hypoxic conditions may protect cancer cells from the insult 
of chemotherapeutic and radiation therapy by preventing cells from actively cycling and 
thus decreasing their susceptibility to DNA damaging agents.  Chapter 5 will explore the 
functional consequences of Cdc25A suppression on cell cycle progression to gain further 
perspective on the regulation of the cell cycle by hypoxia. 
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4 IDENTIFICATION OF THE ROLE OF HIF-1? IN REGULATION OF 
CDC25A BY HYPOXIA 
?
4.1 INTRODUCTION 
?
Cells undergo a variety of cellular responses when placed under hypoxic conditions. 
These responses include the activation of signaling pathways that regulate cell 
proliferation, angiogenesis and cell death.  Cancers cells have harnessed these pathways 
allowing them to survive under hypoxic conditions.  HIF-1? is an important mediator of 
the cellular response to hypoxia, which has been hypothesized to regulate Cdc25A in 
human cancer cell lines (82). A possible role for HIF-1? is supported by evidence that 
HIF-1? can actually disrupt expression of c-Myc driven genes and also is required for 
cell cycle arrest (141, 172).  Thus, Cdc25A may represent a key piece of the HIF-1-?-
mediated response to hypoxia in cancer cells.  The following study examined the 
requirement for HIF-1? in the repression of Cdc25A and the induction of hypoxia-
mediated cell cycle arrest in the colon cancer cell line HCT116. 
 
 
 
? 70 
4.2 RESULTS 
 
4.2.1 THE ROLE OF HIF-1? IN HYPOXIA-MEDIATED DOWNREGULATION 
OF CDC25A 
?
Figures 7 and 17 demonstrate that HIF-1? was rapidly and robustly stabilized in response 
to hypoxia in two independent colon cancer cell lines (HCT116 and DLD1).  An isogenic 
HCT116 cell line lacking HIF-1? (HCT116 HIF-1? -/-) was used to determine if the 
presence of HIF-1? was required for the reduction in Cdc25A phosphatase levels. 
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Figure 21: p21 but not HIF-1? is required for hypoxia-mediated loss of Cdc25A. 
p21-/- HCT116, HIF-1? -/- HCT116 and WT HCT116 cells were cultured under normoxic or hypoxic 
conditions for 24 hours after which Cdc25A, Cdc25B, Cdc25C, HIF-1?, p21 and ?-tubulin levels were 
determined by Western blotting.  Western blots are representative of three independent experiments (N=3). 
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These cells were exposed to hypoxic conditions for 24 hours followed by analysis of 
Cdc25A levels by Western blotting.  As can be seen in Figure 21, the absence of HIF-1? 
expression did not abrogate the hypoxia-mediated loss of Cdc25A suggesting that HIF-1? 
is not required for suppression of Cdc25A by hypoxia.  Induction of HIF-1? in HCT116 
cells by the hypoxia-mimetic cobalt chloride (Figure 22) resulted in an increase in HIF-
1? levels but did not decrease Cdc25A indicating that HIF-1? induction alone was 
insufficient to recapitulate the phenotype observed in hypoxic cells. 
Interestingly, hypoxia caused an increase in p21 levels in HIF-1? -/- HCT116 cells.  This 
was particularly interesting given that it has been reported that HIF-1? can actually 
increase p21 expression (172). 
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Figure 22: Cobalt chloride treatment does not suppress Cdc25A protein. 
HCT116 cells were treated with 200 μM cobalt chloride for 0 to 24 hours followed by harvesting of whole-
cell lysates.  Cdc25A and HIF-1? protein levels were determined by Western blotting.  ?-tubulin levels 
were used as a loading control.  Western blots are representative of three independent experiments (N=3). 
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4.3 DISCUSSION 
 
HIF-1? is a critical mediator of the cellular response and the adaptation of cells to low 
oxygen conditions.  HIF-1? levels are increased in a number of human cancers and 
elevated HIF-1? levels are associated with disease progression (216, 217).  Intriguingly, 
these studies have also correlated high levels of HIF-1? with increased cell proliferation 
in a number of human cancers including colon cancer (217).  It was therefore conceivable 
that the repression of Cdc25A observed in hypoxic cells may be dependent on HIF-1. 
In this study I confirmed that HIF-1? was not required for the loss of Cdc25A.   This 
study has also shown that Cdc25A was not affected by hypoxia-mimetics, such as cobalt 
chloride, which act to mimic the stabilizing effect of hypoxia on HIF-1?.  In other words 
cells must be placed under bone fide hypoxic conditions in order to repress Cdc25A.  The 
findings in this study suggest that the regulation of Cdc25A under hypoxic conditions is 
triggered by a hypoxia sensing mechanism that is independent of HIF-1?.  It is now 
recognized that a number of mechanisms with different sensitivities may effectively act 
as oxygen sensors and coexist in the same cell (218).  These mechanisms can broadly 
classified into those dependent on perturbations in mitochondrial function and those 
relying on the synthesis or degradation of mediators.  In the model used in this study it is 
more likely that the latter sensors are involved given the notion that mitochondrial 
function is not affected by moderate hypoxia (1% oxygen).  The redox state of the cell as 
well as the production of reactive oxygen species have been described to function as 
oxygen sensors (218).  A recent study has described the regulation of Cdc25A by 
nitrosative stress has demonstrated that these entities may be able to play a role in the 
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regulation of Cdc25A under hypoxic conditions.  It remains to be determined if moderate 
hypoxia used in this study elicits changes in the redox state of cells and if reactive oxygen 
species are generated and ultimately if these sensors are linked to p21 and miR-21 to 
drive repression of Cdc25A.  Another possible explanation for the HIF-1?-independent 
regulation of Cdc25A under hypoxic conditions is through inhibition of oxygen-sensitive 
prolyl hydroxylases.  Enzymatic hydroxylation of residues within proteins is a novel 
mechanism of signal transduction and given the dependence of these enzymes on oxygen, 
hydroxylation, or the absence of, could modulate the activity of signaling pathways under 
hypoxic conditions.  Although prolyl hydroxylases and their functions in HIF-1? 
stabilization have been extensively studied (219-221), they also have functions in other 
signaling pathways that remain to be fully characterized.  For example, hydroxylases are 
involved in the regulation of I?B, an important mediator of the NF-?B pathway, and in 
the modulation of RNA polymerase II (222).  It therefore seems likely that protein 
hydroxylation may play a role in HIF-1? independent responses to hypoxia and may be 
involved in the repression of Cdc25A by p21 and miR-21.  Further studies are needed to 
determine the identity of the oxygen sensing mechanism responsible for increasing miR-
21 and driving miR-21 and p21 mediated repression of Cdc25A under hypoxic 
conditions. 
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5 HYPOXIA-MEDIATED CELL CYCLE ARREST 
 
5.1 INTRODUCTION 
 
Cdc25A is a critical regulator of the mammalian cell cycle and is required for cell cycle 
progression and mitosis.  Hypoxia is an important aspect of the tumor microenvironment 
and elicits a plethora of changes in cellular behavior affecting amongst other things 
cellular metabolism, proliferation and apoptosis.  The present study has established that 
Cdc25A mRNA levels are decreased in a p21 and miR-21 dependent fashion in response 
to hypoxia.  The induction of cell cycle arrest in response to loss of Cdc25A is well 
established (45, 71, 223).  The aim of this study was to test the hypothesis that the 
observed hypoxia-mediated repression of Cdc25A and respective actions of p21 and 
miR-21 were also required for hypoxia-mediated cell cycle arrest.   
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5.2 RESULTS 
?
5.2.1 INDUCTION OF CELL CYCLE ARREST BY HYPOXIA 
 
Extended periods of hypoxia (24-48 hours) were shown to inhibit proliferation of 
HCT116 cells without induction of cell death (Figure 23). Visual inspection of cells and 
staining with Trypan blue did not indicate an increase in non-viable cells between 
normoxic and hypoxic cultures.  The inhibition of cell proliferation and repression of 
Cdc25A are temporally similar, occurring within about 24 hours after exposure to 
hypoxia and warranting an analysis of the cell cycle distribution in these cell populations. 
Incubation of HCT116 cells under hypoxic conditions for 24 and 48 hours resulted in a 
significant decrease in the late G2/early M phase population (PH3-positive cells) (Figure 
24A).  Examination of the DNA content of these cells reveled an increase in the S- phase 
portion of the population along with decreased mitotic cells suggesting that cell cycle 
arrest is induced in response to hypoxia (Figure 24B).   
I performed mitotic trapping studies to determine if HCT116 cells incubated under 
hypoxic conditions for 24 hours and then treated with nocodazole for an additional 24 
hours were able to reach mitosis or if they are becoming arrested at an earlier phase of the 
cell cycle.  These studies confirm that cell cycle arrest is being induced rather than a 
delay in cell cycle progression. A delay in cell cycle progression, in particular S-phase, 
can occur under conditions limiting the availability of deoxyribonucleotides or by DNA 
lesions hindering replication fork progression (224).  Hypoxia has been shown cause both 
decreased deoxyribonucleotide supplies and replication fork stalling.  Normoxic cells 
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were trapped in the G2/M phase (Figure 25, white bars), hypoxic cells on the other hand, 
did not accumulate in early mitosis, indicative that these cells are arresting at an earlier 
point in the cell cycle either in G1, S or early G2 phase (Figure 25, black bars).  These 
findings indicate that hypoxic cells are arresting prior to the addition of nocodazole and 
because of this, no accumulation of cells in G2/M is observed.  Normoxic cells are still 
actively cycling at 24 hours (24 hours of normoxia followed by 24 hours in the presence 
of nocodazole) and therefore accumulate in the G2/M phase in the presence of the mitotic 
inhibitor nocodazole. 
These data demonstrate that under hypoxic conditions, HCT116 cells undergo cell cycle 
arrest with similar kinetics as the observed loss of Cdc25A protein and in agreement with 
the consequence of Cdc25A suppression. 
 
?
Figure 23: Cell proliferation is inhibited by hypoxia. 
Time course profile of HCT116 cell growth under hypoxic and normoxic conditions.  HCT116 cells were 
counted after indicated periods of time under normoxic (?) or hypoxic conditions (?).  Data is presented 
as the mean ± SEM (n=3).  * = P < 0.05. 
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Figure 24: Loss of the mitotic fraction of cells and S-phase arrest with hypoxic 
exposure. 
HCT116 Cells were cultured under hypoxic conditions for 24 and 48 hours and stained with phospho-
histone H3 and PI.  A) Dot plots indicating DNA content and percentage of mitotic cells (phospho-histone 
H3 positive cells in hexagon).  B) Cell cycle distribution under normoxic and hypoxic conditions after 48 
hours based on DNA content. Cell cycle distribution was determined using ModFit software.  Data are 
presented as mean ± SEM bars (N=3). 
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Figure 25: Induction of S-phase arrest in hypoxic cells. 
HCT116 cells were subjected to mitotic trapping.  Cells were exposed to hypoxia for 24 hours followed by 
an additional 24 hours in the presence or absence of 100 ng/mL nocodazole.  Cells were harvested and 
stained with a phospho-histone H3 antibody and PI followed by analysis by flow cytometry.  Data are 
presented as mean ± SEM bars. Cell cycle distribution was determined using ModFit software (N=3). 
 
Unsynchronized HCT116 cells were incubated under hypoxic conditions for 48 hours and 
then stained with bromodeoxyuridine (BrdU) and 7-actinomycin D (7-AAD) to establish 
if hypoxic cells are arresting in S-phase.  BrdU is taken up by cells actively undergoing 
DNA synthesis, and therefore in S-phase, and 7-AAD stains DNA  (Figure 27).  
Normoxic cell populations were found to have about 50% of cells actively going through 
S-phase, which under hypoxic conditions was reduced by approximately 40% indicative 
of cells undergoing S-phase arrest.   
p53 is a modulator of the cellular response to stress and DNA damage.  The absence of 
p53 in HCT116 cells did not affect hypoxia-mediated repression of Cdc25A and as can 
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be seen in Figure 26, p53 -/- HCT116 cells exhibited a similar phenotype to the isogenic 
WT HCT116 cells (Figure 24A) indicative that p53 was also not required in the induction 
of cell cycle arrest in response to hypoxia.  HCT116 cells were treated with hydroxyurea, 
an agent that causes S-phase arrest via the depletion of deoxyribonucleotides and 
induction of double strand breaks, to confirm that HCT116 cells are in fact capable of 
undergoing S-phase arrest.  As expected an almost complete loss BrdU positive cells was 
observed indicating that these cells can undergo S-phase arrest (Figure 27).   Similar 
experiments were performed in p21 -/- HCT116 cells revealing that like WT cells, 
hydroxyurea was capable of inducing S-phase arrest (Figure 27).  
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Figure 26: p53 is not required for hypoxia-mediated cell cycle arrest. 
p53 -/- HCT116 cells were exposed to hypoxia for 24 and 48 hours or maintained under normoxic 
conditions for 48 hours and stained with an anti-phospho-histone H3 antibody and propidium iodide for the 
detection and evaluation of mitotic cells (contained in the hexagon) and DNA content respectively. (N=3). 
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 However, hypoxia did not elicit a significant reduction in S-phase cells after 48 hours in 
p21-/- HCT116 cells indicating that p21 was required for down regulation of Cdc25A and 
also for induction of cell cycle arrest.  It must be noted that p21-/- cells have a 
proliferative defect that slows down the cell cycle leading to a reduced population size of 
cells undergoing S-phase (225). 
Taken together these data indicated that moderate hypoxia induced p21-dependent cell 
cycle arrest and that this arrest appeared to block cells in S-phase as would be expected 
from Cdc25A suppression. 
 
 
Figure 27: p21-dependent induction of S-phase arrest. 
BrdU staining of WT and p21-/- HCT116 cells exposed to 48 hours hypoxia or 1 mM hydroxyurea as a 
control for induction of S-phase arrest.  BrdU positive cells are indicated in the polygons.  Percentages 
indicate the proportion of cells in S-phase (BrdU positive).  The dot plots are representative of three 
separate experiments (N=3).   
 
? 81 
5.2.2 REQUIREMENT OF HIF-? FOR HYPOXIA-MEDIATED CELL CYCLE 
ARREST 
 
The induction of cell cycle arrest in response to hypoxia has been discussed in the 
Chapter 1. One study concluded that HIF-1? is required for cell cycle arrest (141). 
However, this study was conducted in non-transformed cells and the same dependence on 
HIF-1? may not exist in cancer cells. WT and HIF-1? -/- cells were exposed to hypoxia 
for 48 hours and then stained with an anti-phospho-histone H3 (PH3) antibody to detect 
mitotic cells and propidium iodide (PI) to determine DNA content providing an 
indication of whether cells are in the G1 or G2 phase of the cell cycle.  As can be seen in 
Figure 28, HIF-1? -/- cells did not arrest under hypoxic conditions as indicated by the 
presence of mitotic cells in the hypoxic population as well as no apparent change in the 
distribution of cells based on DNA content compared with WT cells.  These findings 
demonstrate that HIF-1? was required for cell cycle arrest under hypoxic conditions in 
colon cancer cells. 
 
 
5.2.3 MIR-21 AS A REGULATOR OF HYPOXIA MEDIATED CELL CYCLE 
ARREST 
 
mir-21 has been established as a regulator of Cdc25A under hypoxic conditions and has 
been shown to be upregulated in hypoxic HCT116 cells (Figure 19).  The role of miR-21 
dependent Cdc25A suppression on the cell cycle was determined using DLD1 WT and 
? 82 
DLD1 miR-21 KO cells that were exposed to hypoxia for 48 hours and then analyzed for 
BrdU incorporation and DNA content (7-AAD staining) (Figure 29).  WT cells exhibited 
a hypoxia-dependent reduction in BrdU incorporation indicative of S-phase arrest 
(approximately 56%).  This effect was comparable to that observed in HCT116 cells 
exposed to hypoxia for 48 hours (Figure 27). 
 
?
 
Figure 28: HIF-1? -/- cells do not undergo hypoxia-induced cell cycle arrest. 
WT and HIF-1? -/- HCT116 cells were exposed to hypoxia for 48 hours or maintained under normoxic 
conditions for 48 hours prior to staining with anti-phospho-histone H3 (PH3) and propidium iodide (PI).  
20,000 cells were counted for each condition by flow cytometry. Percentages indicate the proportion of 
cells contained in the polygon gates representing cells in mitosis (PH3 positive) contained in the polygons. 
The experiment shown is representative of three independent experiments (N=3). 
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The miR-21 KO cells on the contrary did not exhibit a significant change in BrdU 
incorporation following hypoxic exposure (approximately 8% decrease in S-phase cells).  
These data indicated that miR-21 was not only required for repression of Cdc25A but 
also for induction of S-phase arrest in hypoxic cells. 
 
?
 
Figure 29: Hypoxia induces miR-21 dependent S-phase arrest.  
DLD1 WT and miR-21 KO cells were cultured under hypoxic conditions for 48 hours and then stained with 
BrdU and 7-AAD and analyzed by flow cytometry.  BrdU positive cells are indicated in the polygons.  
Percentages indicate the proportion of cells in S-phase (BrdU positive).  The dot plots are representative of 
three separate experiments (N=3). 
 
? 84 
5.3 DISCUSSION 
 
Loss of Cdc25A in response to DNA damage results in S-phase cell cycle arrest. In fact, 
Cdc25A has been shown to be rate limiting for entry into S-phase by activation of CdK2 
(45, 223).  In the present study, it has been shown that repression of Cdc25A mRNA 
levels by hypoxia elicited a p21- and miR-21-dependent cell S-phase cell cycle arrest.  
Hypoxia has for some time been known to cause cell cycle arrest but the mechanisms by 
which cells sense hypoxia and subsequently relay signals to undergo cell cycle arrest are 
poorly understood.  Severe hypoxia causes rapid S-phase arrest as a result of checkpoint 
activation leading to the engagement of checkpoint kinases (143, 148, 149, 165).  The 
role of Cdc25A in cell cycle arrest induced by severe or moderate hypoxic conditions has 
not been reported.  The data shown herein demonstrated that Cdc25A could be modulated 
at the level of gene expression and mRNA stability by p21 and miR-21 respectively and 
that suppression of Cdc25A resulted in S-phase arrest in response to moderate hypoxia.   
This study provides a possible mechanism for the induction of S-phase cell cycle arrest 
through the repression of Cdc25A, resulting in inactivation of Cdk/Cyclin complexes 
independently of checkpoint activation.  The role of Cdc25A in modulating the cell cycle 
has been extensively studied (71, 75, 226-228) with the regulation of Cdc25A in response 
to DNA damage and other cellular stresses being mediated by increased Cdc25A 
degradation following phosphorylation of the phosphatase and through decreased gene 
expression via transcriptional repression (80, 81). The degradation of Cdc25A protein 
occurring very rapidly and the gene repression being a more delayed sustained response. 
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The dependence of hypoxia-induced S-phase arrest on p21 may be due to transcriptional 
repression of Cdc25A or due to the action of p21 as inhibitor of Cdk2/Cyclin E.  
Repression of Cdc25A mRNA levels by p21 has been described in response to DNA 
damage and has been shown to occur by direct binding to the Cdc25A promoter (80, 81).  
The latter study has described this mechanism to be dependent on p53 in contrast to the 
present study where p53 -/- HCT116 cells arrested in a similar fashion to the WT 
HCT116 cells.  The induction of cell cycle arrest by direct inhibition of Cdk2/Cyclin E is 
less likely given that p21 levels were not increased in HCT116 cells following induction 
of hypoxia for 24 hours.  Previous studies have shown that p21 levels are increased in 
response to DNA damaging agents by p53-dependent and -independent mechanisms 
leading to inhibition of cell cycle progression by Cdk2 inhibition and transcriptional 
repression (80).  In the present study, no detectable increases in p21 protein levels were 
observed under hypoxic conditions, consistent with the findings of others (149).  This 
raises the question as to whether the transcriptional repression capability of p21 requires 
an increase in protein levels or if basal p21 levels under hypoxic conditions can induce 
transcriptional repression?  It has been suggested that p21 may not be required for the 
initial induction of cell cycle arrest but instead for the maintenance of arrest and 
prevention of cell cycle resumption (149).  Testing this hypothesis will yield important 
information into the mechanisms of hypoxia-mediated cell cycle arrest. 
HIF-1? regulates the expression of a large number of hypoxia responsive genes but is 
also able to repress the expression of genes involved in regulation of the cell cycle such 
as p21 (172).  Under hypoxic conditions, HIF-1? can counteract c-Myc repression of p21, 
thus increasing levels of the CdkI and inducing G1/S cell cycle arrest.  In contrast to the 
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previous findings, the present study has shown that HIF-1? was required for induction of 
cell cycle arrest without a detectable increase in p21(Figure 21).  The absence of an 
increase in p21 may be due to the fact that p21 levels were examined after 24 hours and a 
hypoxia-mediated increase in p21 may occur earlier.  Another explanation is that the 
HCT116 cells used in this study are not completely isogenic and the p21 pathway may 
have been altered.  This notion might also explain why cells lacking HIF-1? had 
increased p21 under hypoxic conditions, contrary to what would be expected if HIF-1? is 
responsible for increasing p21.  It has also been suggested that alterations in the cell lines 
used in this study may preclude a robust induction of p21.  Indeed HCT116 cells have an 
altered p21 response even upon induction of DNA damage (229).  Further investigation 
into the non-transcription effects of HIF-1? and its relationship with p21 are warranted.  
Interestingly, the role of HIF-1? in the present study initially appears to be contrary to 
notion that HIF-1? promotes tumor growth. 
Hypoxia-inducible genes are known to regulate multiple biological pathways including 
cell proliferation, angiogenesis, cellular metabolism, apoptosis, immortalization and 
migration (125).  Many known oncogenic pathways overlap with hypoxia-induced 
pathways and cancer cells may take advantage of these pathways during tumorigenesis. 
Whereas a number of the pathways activated by HIF-1? promote tumor growth by 
triggering cell proliferation and resistance to apoptosis, the response to hypoxia observed 
in the present study does not appear to directly promote tumorigenesis although the 
inhibition of cell cycle progression under hypoxic conditions may represent a protective 
mechanism for cells in order to avoid death and resist DNA damage-inducing agents. 
More research is needed to reconcile the seemingly paradoxical roles of HIF-1? in 
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cancer. One possibility is that in some of the studies mentioned above, HIF-1? 
overexpression was an important factor in the establishment of tumorigenic phenotypes 
whereas in the model used in this study, HIF-1? levels were transiently increased by 
hypoxia but the transcription factor was not overexpressed by ectopic expression as has 
been the case in a number of studies.  The correlation between HIF-1? levels and 
tumorigenicity raises the question as to whether HIF-1? leads to more aggressive tumors 
or if aggressive tumors generate higher levels of HIF-1?? 
The ability to survive under hypoxic conditions distinguishes tumor cells from normal 
cells.  Both normal and transformed cells display a wide array of hypoxic responses 
dependent and independent of HIF-1? but the exact pathways involved in each case 
remain to be determined. The regulation of Cdc25A under hypoxic conditions does not 
require HIF-1? but the subsequent cell cycle arrest is abrogated in cells lacking of HIF-
1?. These findings suggest that HIF-1? is contributing to hypoxia-mediated cell cycle 
arrest by a mechanism that may compensate for the loss of Cdc25A such as increased 
expression of the kinases involved in inhibitory phosphorylations of Cdks. In addition, it 
is possible that HIF-1? is causing the inhibition of Cdk2 independently of Cdc25A 
resulting in a similar phenotype of cell cycle arrest.  This data reinforces the importance 
of HIF-1? in the cellular response to hypoxia and is in agreement with the concept that 
inhibiting HIF-1? in tumor cells and forcing cells to cycle in the presence of DNA 
damaging agents may represent an attractive target for cancer therapy (125, 230).  
The recent discovery of a novel method of Cdc25A regulation at the level of translation 
in response to nitrosative stress (231) indicates that proteasome-mediated degradation of 
Cdc25A and decreased gene expression are not the sole mechanisms of Cdc25A 
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regulation in response to cellular stresses.  This study presents evidence for yet another 
novel mechanism of regulation of Cdc25A by miR-21 in response to hypoxic stress.  It is 
proposed that miR-21 is required not only for decreased Cdc25A mRNA and protein 
levels but also for S-phase replication arrest. miR-21 is overexpressed in numerous 
cancer types including colon cancer and its role in the regulation of the cell cycle through 
repression of Cdc25A may shed light on the phenomenon of increased therapeutic 
resistance of hypoxic tumors. The resistance of hypoxic tumors chemotherapeutic drugs 
and radiation therapy is based on the poor accessibility of drugs to the tumor sight due to 
aberrant angiogenesis but also due to the absence of molecular oxygen required for 
radiation and chemotherapy induced DNA damage.  For effective induction of DNA 
damage and subsequent apoptosis, cells must be actively cycling.  The fact that hypoxia 
also induces cell cycle arrest could diminish the effectiveness of DNA damaging agents 
thus protecting cells from sustaining DNA damage and undergoing apoptosis.  mir-21 is 
increased in hypoxic cells and is required for both repression of Cdc25A and also for 
hypoxia-mediated cell cycle arrest.  It is conceivable that under hypoxic conditions, 
upregulation of miR-21 resulting in suppression of Cdc25A represents a protective 
mechanism allowing cells to survive and remain viable under hypoxic conditions.  
Although miR-21 is increased in hypoxic cells, its mechanism of regulation remains to be 
discovered.  The independence of Cdc25A suppression from HIF-1?, suggests that 
increases in miR-21 in response to hypoxia may also be independent of the hypoxia-
responsive transcription factor.  The role of miR-21 in tumorigenesis has been largely 
associated with the promotion of tumor growth, invasion and metastasis, increased cell 
proliferation and inhibition of apoptosis (175, 232, 233) and the targets of miR-21 
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leading to these phenotypes are primarily the products of tumor suppressor genes (232).  
In the present study, miR-21 appears to be negatively regulating the levels of Cdc25A, a 
proto-oncogene.  This effect may have come about evolutionarily to protect cells from 
hypoxia and is conserved in cancer and possibly promoted by increased miR-21 
expression levels. 
The findings in this study along with the frequent overexpression of miR-21 in human 
cancer make this miR an attractive target for cancer therapy and its inhibition may 
represent a new tool in overcoming the resistant phenotype of hypoxic tumors.  The data 
presented in this study appears to conflict with the finding that miR-21 is overexpressed 
in human cancers and so is Cdc25A.  If miR-21 negatively regulates Cdc25A, then it 
would be expected that Cdc25A would not be overexpressed.  It is however possible that 
tumors found to overexpress miR-21 do not overexpress Cdc25A and vice versa.  
Another important aspect is that although hypoxia represents an important feature of the 
tumor microenvironment, it is typically transient and therefore the function of miR-21 in 
the regulation of Cdc25A may differ from it’s role in tumorigenesis in the absence of 
hypoxia. In summary, the data shown herein describes a novel, hypoxia-mediated, 
mechanism for the regulation of the cell cycle.  At the center of this pathway is Cdc25A, 
which upon downregulation can induce cell cycle arrest.  The downregulation of Cdc25A 
appears to be controlled by two mediators:  mir-21, which is upregulated in response to 
hypoxia, and p21, which has also been shown to be increased by hypoxia and is known to 
repress Cdc25A gene expression.  Both of these mediators are needed for repression of 
Cdc25A and induction of cell cycle arrest.  Whether there is a link between p21 and miR-
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21 remains to be determined as does the mechanism of miR-21 upregulation under 
hypoxic conditions.   
 
 
6 CONCLUSION 
 
The role of the tumor microenvironment in tumorigenesis is becoming clear and 
modulation of the cell cycle represents an important adaptation conferring a survival 
advantage to cancer cells.  Tumor hypoxia has been shown to promote tumorigenesis and 
is proposed to be a major factor in the resistance of solid tumors to chemo- and radiation 
therapy.  The changes in the physiology associated with tumor growth that lead to 
hypoxic regions has been well studied, however, the molecular pathways involved in the 
cellular response to hypoxia leading to changes in cell cycle progression and cell 
proliferation remain poorly described. In the design of this study, it was hypothesized that 
Cdc25A is an essential mediator in the process of hypoxia-mediated cell cycle arrest. The 
data in this study has revealed a novel mechanism for the regulation of Cdc25A and it is 
proposed that via Cdc25A-dependent modulation of the cell cycle, hypoxic cells undergo 
S-phase arrest, an event that may confer a survival advantage to cancer cells under 
sustained hypoxic conditions.  This study provides evidence that under hypoxic 
conditions, colon cancer cells downregulate the levels of the phosphatase Cdc25A 
through a mechanism of decreased mRNA levels involving miR-21 and p21.  This 
represents a previously unknown mechanism of regulation of Cdc25A and cell cycle 
progression.  The role of miR-21 in the regulation of Cdc25A observed in this study is 
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substantiated by the findings that miR-21 is upregulated in response to hypoxia and that 
Cdc25A is a putative target for miR-21.  A novel method of Cdc25A regulation at the 
level of translation in response to nitrosative stress has recently been described (231, 234) 
indicating that proteasome-mediated degradation of Cdc25A and decreased gene 
expression are not the sole mechanisms of Cdc25A regulation in response to cellular 
stresses.  The implications of this new pathway may extend beyond the boundaries of 
cancer and the discovery of a novel mode of cell cycle regulation under hypoxic 
conditions may also contribute to our understanding of the pathophysiologies of several 
other diseases including cardiac hypertrophy, acute and chronic vascular disease, 
pulmonary disease, stroke, and Alzheimer’s disease where hypoxia may play an 
important role in disease progression and Cdc25A overexpression has been reported.  
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APPENDIX A 
?
ANTIBODIES FOR WESTERN BLOTTING 
 
Antigen  Antibody species Dilution Vendor  
Cdc25A (F-6)  Mouse  1:100  Santa Cruz Biotechnology  
Cdc25B  Mouse  1:2500  BD Pharmingen  
Cdc25C  Rabbit  1:1000  Santa Cruz Biotechnology  
Chk1  Rabbit  1:5000  Santa Cruz Biotechnology  
Chk2  Mouse  1:200  Santa Cruz Biotechnology  
HA  Mouse  1:1000  Covance Research Products, Inc. 
HIF-1? Mouse 1:250 BD Pharmingen  
p21  Rabbit  1:500  Calbiochem  
Phospho-Chk1 (Ser245) Rabbit 1:1000 Cell Signaling Technology 
Phospho-Chk2 (Thr68) Rabbit 1:1000 Cell Signaling Technology 
?-Tubulin  Mouse  1:20,000 Cederlane Laboratories  
?
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